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ABSTRACT 
 
Introduction: Aflatoxin B1 (AFB1) is produced by filamentous fungal strains of Aspergillus flavus 
and Aspergillus parasiticus that infect field crops, therefore AFB1 is a frequent contaminant of 
dietary staples such as rice, maize and peanuts. Humans and animals are exposed to AFB1 through 
consumption of contaminated foods, predisposing them to various diseases. AFB1 is a potent 
hepatotoxin that has been classified by the International Agency of Research on cancer (IARC) as 
a group1 carcinogen. The carcinogenic effects of AFB1 have been attributed to the metabolism of 
this toxin to an epoxide that promotes the production of free radicals, mitochondrial toxicity and 
induction of cell death. With the increasing prevalence of kidney associated diseases in humans, 
and the AFB1-associated kidney toxicity observed in animals, this study investigated the cytotoxic 
effects/mechanism of AFB1 in human embryonic kidney (Hek293) cells. 
Methods: Hek293 cells were exposed to AFB1 (0-100µM) for 24hrs. The effect on cell viability 
was assessed using the methylthiazol tetrazolium (MTT) assay, which also produced the half 
maximal inhibitory concentration (IC50) used in subsequent assays. Free radical production was 
evaluated by quantifying malondialdehyde (MDA) and nitrate concentration, while DNA 
fragmentation was determined using the single cell gel electrophoresis (SCGE) assay and DNA gel 
electrophoresis. Damage to cell membranes was ascertained using the lactate dehydrogenase 
(LDH) assay. The concentration of ATP, reduced glutathione (GSH), necrosis, annexin V and 
caspase activity was measured by luminometry. Western blotting and quantitative PCR was used 
to assess the expression of proteins and genes associated with apoptosis and oxidative stress. 
Results and discussion: The MTT assay revealed a reduction in cell viability of Hek293 cells as 
the AFB1 concentration was increased, with a half maximum inhibitory concentration (IC50) of 
32.60 µM. The decreased viability corresponded to decreased ATP concentration. The upregulation 
of Hsp70 indicated that oxidative stress was induced in the AFB1-treated cells. While this implies 
an increased production of free radicals, the accompanying upregulation of the antioxidant system 
indicates the activation of defense mechanisms to prevent cellular damage. Thus, membrane 
damage associated with increased radical formation was prevented as indicated by the reduced 
LDH release and necrosis. In addition, cytotoxic effects were evident as AFB1 activated the 
intrinsic pathway of apoptosis with corresponding increased DNA fragmentation, p53 and Bax 
upregulation and increased caspase activity, but externalisation of phosphatidylserine (PS), a major 
hallmark of apoptosis, did not occur in AFB1 treated Hek293 cells.   
xviii 
 
Conclusion: The results suggest that AFB1 induced oxidative stress leading to cell death by the 
intrinsic pathway of apoptosis in Hek293 cells. 
Keywords : Aflatoxin B1 (AFB1), oxidative stress, apoptosis, Hek293 cells   
1 
 
CHAPTER 1 : INTRODUCTION 
 
1.1 BACKGROUND 
 
Fungi belonging to Aspergillus, Penicillium and Fusarium genera are frequent contaminants of a 
variety of agricultural commodities that form part of the South African staple diet (da Rocha et al., 
2014, Alshannaq and Yu, 2017, Misihairabgwi et al., 2019). These contaminating fungi produce 
toxic low molecular weight secondary metabolites (mycotoxins) due to compromised 
environmental conditions such as high temperatures and increased humidity (Liu and Wang, 2016). 
Mycotoxins persist in food despite cooking and processing, and consumption of contaminated food 
commodities can cause diseases and death in humans and animals (da Rocha et al., 2014). 
 
Aflatoxins are mycotoxins that are produced by the filamentous fungi Aspergillus flavus and 
Aspergillus parasiticus that are found on peanuts, wheat, corn, beans and rice products (de Oliveira 
and Corassin, 2014, Alshannaq and Yu, 2017). It is postulated that aflatoxin B1 (AFB1) is the most 
potent member of the aflatoxin family, and has been classified as a group 1 carcinogen by the  
International Agency for Research on cancer (IARC) (Chen et al., 2016). The carcinogenic effects 
of AFB1 are based on its metabolism; AFB1 is bioactivated to a potent AFB1-8,9-epoxide by 
cytochrome P450 (CYP), but this can be detoxified by the phase 2 glutathione (GSH) pathway 
(Kumar et al., 2017, Deng et al., 2018). The AFB1-8,9-epoxide targets guanine residues of DNA 
forming adducts that result in well-known mutations associated with adduct formation, most 
notably the Ras oncogene and p53. The epoxide also forms adducts at lysine residues of proteins, 
as observed with albumin, the albumin-lysine adduct is used as a biomarker for AFB1 exposure 
(Rushing and Selim, 2018). 
 
Aflatoxin B1 exposure is implicated in hepatocellular carcinoma and increased lung cancer risk. 
Cytotoxic effects related to these organs have been demonstrated in human hepatocellular 
carcinoma (HepG2) cells (Liu et al., 2014, Li et al., 2017) and human bronchial epithelial (BEAS-
2B) cells (Zhang et al., 2014) . Oxidative stress is one mechanism that may pre-dispose to AFB1-
induced cell injury, because free radical damage to DNA and protein are associated with 
carcinogenesis. AFB1 exposure is also linked to aberrant cell death mechanisms especially 
apoptosis. In addition to its carcinogenic capability, previous studies have reported that AFB1 is 
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also mutagenic, genotoxic and immunotoxic to mammals (Kumar et al., 2017). Studies also 
demonstrate AFB1 to be nephrotoxic and induce renal damage in rats, and suggests that prolonged 
exposure has the potential to induce kidney disease (Abdel-Hamid and Firgany, 2015, Kumar et 
al., 2017, Asa et al., 2018, Yilmaz et al., 2018). However, the biochemical mechanism underlying 
the mechanism of AFB1 effects in human kidney has not been elucidated. 
 
Kidney damage in rats is not surprising since the kidney is the principal route for excretion of 
biotransformed water-soluble metabolites (Pizzorno, 2015). Drugs and metabolites are selectively 
taken up and concentrated by the renal tubular cells before excretion in the urine, therefore high 
intracellular concentrations of toxic substances may be retained mainly in the renal medulla 
(Pizzorno, 2015, Câmara et al., 2017). As a result, direct toxic damage to renal tubules and renal 
papillae may predispose to kidney disease  (Câmara et al., 2017). 
 
Apart from a variety of physiological functions performed by the kidneys, they also possess 
biotransformation capabilities. The kidneys have been reported to express metabolizing enzymes 
cytochrome P450 (CYP) including CYP2B6 which is involved the metabolism of diverse 
environmental chemicals (Zanger and Schwab, 2013). In addition, CYP3A4 and CYP3A5 are also 
expressed in the kidney; it has been reported that CYP3A4 and CYP3A5 are involved in AFB1 
metabolism (Knights et al., 2013, Zanger and Schwab, 2013). 
 
Toxic phase 1 intermediates require conjugation with GSH.  The kidneys are reliant on an adequate 
GSH supply to function normally. This is based on the exposure to high concentrations of oxidants 
and reactive electrophiles (Pizzorno, 2015). GSH protects against oxidative stress which is essential 
for mitochondrial and cellular homeostasis and aids in the detoxification of xenobiotics. 
Detoxification of chemicals involves conjugation with GSH to form GSH adducts that are 
considered less toxic and can be excreted from cells via the mercapturic acid pathway (Pizzorno, 
2015). 
 
1.2  PROBLEM STATEMENT  
Wheat and maize are a major part of the diet, and are considered the most staple foods in South 
Africa  (Misihairabgwi et al., 2019). Maize and its products are highly prone to mycotoxin 
contamination both in the field and in storage. One of the potent mycotoxins elaborated, AFB1, is 
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considered the most toxic amongst mycotoxins and has been reported to possess carcinogenic, 
mutagenic and hepatoxic effects, which confer major health risks to humans and animals. 
Moreover, it has been linked to the development of hepatocellular carcinoma (Deng et al., 2018) 
and nephrotoxic effects in rat kidney (Abdel-Hamid and Firgany, 2015, Asa et al., 2018, Yilmaz 
et al., 2018). Several studies using human cell lines have indicated aberrant apoptosis and oxidative 
stress as mechanisms for AFB1-mediated cytotoxicity. Cytotoxicity to human lymphocytes by the 
induction of apoptosis and necrosis in human lymphocytes has been reported by Al-Hammadi 
(2014)(Al-Hammadi et al., 2014). Pro-apoptotic activity of AFB1 was also demonstrated in HepG2 
and BEAS-2B cells (Liu et al., 2014, Zhang et al., 2014, Li et al., 2017). AFB1 has also 
demonstrated cytotoxicity to human peripheral blood mononuclear cells (PBMCS) by impairment 
of oxidative status (Bernabucci et al., 2011). The biochemical mechanisms underlying the effects 
of AFB1 in kidney cells has not been investigated in humans. Considering the essential role of the 
kidney as an excretory organ in the body, the effects of AFB1 in kidney cells requires investigation.  
 
 
1.3  AIM OF THE STUDY 
This study aimed to determine the cytotoxic effects of AFB1 on human embryonic kidney (Hek293) 
cells.  
 
1.4  HYPOTHESIS 
Null hypothesis: Acute exposure (single dose in 24 hours) to AFB1 has no effect in Hek293 cells. 
Alternate hypothesis: Acute exposure (single dose in 24 hours) to AFB1 induces oxidative stress 
and apoptosis in Hek293 cells. 
 
1.5 OBJECTIVES OF THE STUDY 
This study was conducted to determine the 
• changes in cell viability after administration of various AFB1 concentrations in Hek293 
cells to derive the IC50 
• effect of AFB1 on production of free radicals in Hek293 cells  
• antioxidant responses induced by AFB1 in Hek293 cells 
• cell death pathways triggered by AFB1 in Hek293 cells  
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CHAPTER 2 : LITERATURE REVIEW 
 
This study investigated the effects of aflatoxin B1 (AFB1) on Hek293 cells. The literature review 
established what is known about the mycotoxin AFB1 which colonizes various food commodities 
and is a health concern worldwide. Given the challenges posed by AFB1 in food toxicology, food 
security and public health, this chapter covers what has been reported on the effects of AFB1 on 
human and animal health. It also establishes the gap in literature, since AFB1 effects in the human 
kidney have not been investigated. 
 
2.1 MYCOTOXINS  
Mycotoxins are toxic low molecular weight (below 700kDa) secondary metabolites produced by a 
variety of fungi or mould. There are over 400 different mycotoxins, with new ones still being 
classified (da Rocha et al., 2014, Yao et al., 2015).  The genera Aspergillus, Fusarium, Penicillium 
and Alternaria are deemed as the most mycotoxin producing fungi (da Rocha et al., 2014, Carvajal-
Moreno, 2015). The synthesis of mycotoxins by these toxigenic species depends extensively on the 
internal parameters of fungal strains (biochemical, physical and genetic), but also on external 
factors such as humidity and temperature (Misihairabgwi et al., 2019, Zinedine and El Akhdari, 
2019). Therefore, mycotoxins are produced when fungi reach maturity; and their production can 
occur in the field, before harvest, post-harvest, during processing, packaging, distribution and 
storage in different grains and agricultural commodities (Liu and Wang, 2016).  
 
The occurrence of mycotoxins in human and animal food is a significant problem adversely 
affecting food quality in developing countries as well as developed countries (da Rocha et al., 2014, 
Alshannaq and Yu, 2017). The detrimental effects include a decrease in nutritional value of food 
and reduced yields in crop and livestock. It has been reported that approximately 25-50% of 
products produced worldwide, particularly basic foodstuffs are contaminated with mycotoxins (da 
Rocha et al., 2014, Misihairabgwi et al., 2019). Most mycotoxins are not affected by food 
processing; for example cooking and they can be converted to toxic intermediates by metabolism 
in humans and animals (Alshannaq and Yu, 2017). In addition, the metabolism of mycotoxins to 
their toxic form can potentially pose risks to human health, resulting in disease and death in 
mammals. 
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Exposure to mycotoxins occurs when fungal infected crops are directly consumed by livestock, for 
example wheat, corn, oats and sorghum (Alshannaq and Yu, 2017). However, indirect 
contamination may occur when the toxigenic fungus has been eradicated during processing, but 
the mycotoxins remain in the final product. The main route of exposure to mycotoxins in humans 
is through the ingestion of contaminated plant and animal products, including food derived from 
these products such as cheese, milk and meat (Figure 2.1)  (da Rocha et al., 2014, Alshannaq and 
Yu, 2017). However, inhalation and dermal contact may also be important routes of exposure. 
Direct effects of mycotoxins range from acute disease where exposure to the toxin may result in 
severe health conditions prior to death, these conditions are expected after exposure to high levels 
of mycotoxin (da Rocha et al., 2014, Alshannaq and Yu, 2017, Zinedine and El Akhdari, 2019). 
Chronic disease manifestations may result from prolonged exposure to small quantities of the toxin. 
The diseases resulting from mycotoxin exposure are known as mycotoxicosis. Mycotoxicosis 
usually remain unrecognized except when large numbers of people are affected with no apparent 
connection to a known aetiological agent (Alshannaq and Yu, 2017, Zinedine and El Akhdari, 
2019).  
 
 
 
Figure 2.1 : The main route of exposure to mycotoxins humans and animals (Prepared by author). 
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‘Turkey-X disease’ marked a breakthrough in the association of mycotoxin-contamination with 
disease in animals. The plague occurred in the early 1960’s, and was marked by the death of turkey 
poults in England after consumption of a peanut meal that originated from Brazil and Africa 
(Alshannaq and Yu, 2017). The secondary metabolite responsible for the death of the birds was 
produced by Aspergillus flavus and studies of these toxins ensued. The genus Aspergillus, first 
described in 1729 by Pier Antino Micheli, is more common in warmer tropical and subtropical 
areas than in moderate areas of the world. Aspergillus species are filamentous saprophytic fungi 
that can produce active compounds like aflatoxins, penicillic acid, ochratoxins, citrinin, 
sterigmatocystin and other important metabolites (Yao et al., 2015, Misihairabgwi et al., 2019). 
 
2.2 AFLATOXINS  
Aflatoxins (AFs) are a class of structurally related toxic metabolites produced by the fungal strains 
Aspergillus flavus and Aspergillus parasiticus that are normally found in soil and organic materials 
(Kumar et al., 2017). There are approximately 20 known aflatoxins that are frequently found as 
contaminants in maize grains, cereals, peanuts, rice and oil seeds (de Oliveira and Corassin, 2014). 
There are favourable conditions for aflatoxin production, these include high moisture during 
harvest, dry weather near crop maturity and insufficient drying and storage of crops (Figure 2.2). 
Post harvesting conditions such as storage (long periods of storage, excess heat and moisture, pest 
related damage) and food processing also influences the production of aflatoxins (Figure 2.2). The 
identification of aflatoxins was linked to the discovery that a ground nut contaminated with 
Aspergillus flavus lead to a turkey disease that killed approximately 100 000 turkey poultry birds 
in England (da Rocha et al., 2014, Yao et al., 2015). Aflatoxins therefore pose a threat to human 
and animal health, their toxicity can result in kidney and liver damage, cause carcinogenic, 
mutagenic and immunosuppressive effects (Carvajal-Moreno, 2015). 
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Figure 2.2 : The factors influencing  aflatoxin  production and occurrence in the food chain. Adapted from 
(Fernandes et al., 2017). 
 
2.2.1 Physical and chemical properties of aflatoxins 
Aflatoxins are colourless to pale yellow crystalline solids with low molecular weight and display 
fluorescence under UV light. Aflatoxins are unstable under UV light in the presence of oxygen and 
extreme pH levels (<3 or >10). Under alkaline conditions the lactone ring opens and aflatoxins are 
destroyed, but this is a reversible reaction upon acidification (Kumar, 2018). Ammoniation causes 
irreversible opening of the lactone ring at high temperatures and pressure resulting in 
decarboxylation of aflatoxins (Kumar, 2018). Aflatoxins have high decomposition temperatures 
ranging from 237˚C to 320˚C; this makes them stable at temperatures present when cooking or 
boiling food, milk and alcoholic fermentation (Bbosa et al., 2013c) and their destruction is not 
easily achieved. They are slightly soluble in water and easily soluble in moderately polar solvents 
such as methanol, chloroform and dimethyl sulfoxide (de Oliveira and Corassin, 2014, Kumar, 
2018). Due to the lipid solubility, aflatoxins are readily absorbed from the site of exposure, across 
the cell membranes into the blood stream. They are then distributed to various tissues or organs 
especially the liver where they are biotransformed (Kumar, 2018).  
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2.2.2 Types of aflatoxins 
Of the approximately 20 known aflatoxins, only aflatoxin B1 (AFB1), AFB2, AFG1, AFG2, AFM1 
and AFM2 (Figure 2.3) are usually found in foods. The B and G denotes the blue and green 
fluorescent colours produced under ultraviolet light, while the subscript numbers 1 and 2 indicate 
the major and minor compounds respectively (Deng et al., 2018, Kumar, 2018). Less toxic 
oxidative metabolites of aflatoxin produced by farm animals after ingestion of contaminated feed 
include AFM1, AFM2, AFG1 and AFG2 (Figure 2.3). Even though the metabolites are less toxic 
than the parent compound, AFM1 in dairy milk can cause liver illness in humans especially among 
infants and children (Kumar, 2018). The toxicity of aflatoxins decreases in the order 
B1>G1>B2>G2.    
 
 
 
Figure 2.3 : Different types of aflatoxins, AFB1 (Mw=312.27g/mol), AFB2 (Mw=314.29g/mol), AFG1 
(Mw=328.276g/mol), AFM1 (Mw=328.276g/mol) AFG2 (Mw=330.29g/mol), AFM2 (Mw=330.29 g/mol) 
(Musleh et al., 2017). 
 
2.3 AFLATOXIN B1 
Aflatoxin B1 (AFB1) is found as a contaminant in peanuts and grains such as maize, sorghum and 
rice.  It is the most potent of the aflatoxin family and has been reported to have mutagenic, 
hepatocarcinogenic, teratogenic and genotoxic abilities, it causes immunosuppression in animals 
and can influence how cells are produced in the body (Liu and Wang, 2016).  It has been classified 
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as a group 1 carcinogen in humans by the WHO-international agency for research on cancer (Al-
Ouqaili, 2018). Although AFB1 mainly targets the liver, it also affects other organs and tissue, 
including lungs and kidney. 
 
2.3.1 Structure  
Aflatoxin B1 (C17H12O6) has a difuro-coumaro-cyclopentenone structure fused with a lactone ring 
of the coumarin structure with oxygen (O2) at positions 1, 4 and 11 (Marchese et al., 2018). The 
difuro terminus of this compound has a 2,3 double bond which is essential for the carcinogenicity 
of this toxin (Figure 2.4). On condition that the bond is single, the carcinogenic properties of AFB1 
are lost but toxicity is still retained (Kumar, 2018, Marchese et al., 2018). 
  
 
 
Figure 2.4 : The chemical structure of aflatoxin B1 (C17H12O6) (Hedström and Mattiasson, 2015). 
 
2.3.2 Metabolism 
 
2.3.2.1 The cytochrome P450 (CYP) enzyme system 
Cytochrome P450 (CYP) enzymes are so named because they are bound to membranes within a cell 
(cyto) and comprise of a haem pigment (chrome and P) that absorbs light at a wavelength of 450nm 
when exposed to carbon monoxide (Guengerich, 2015). Each CYP gene is assigned a number that 
relates it to a specific group, a letter that represents the gene’s subgroup and a number given to the 
specific gene within the group (Guengerich, 2015). For example, the cytochrome P450 gene found 
in group 3, subgroup A and gene 1 will be written as CYP3A1. There are about 60 CYP genes in 
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humans (Raunio et al., 2015). The CYP family play a role in the synthesis and metabolism of 
numerous endogenous molecules and chemicals including cholesterol, steroid hormones and bile 
acids. They also break down xenobiotics like ingested medication and toxins found within cells 
(Knights et al., 2013, Raunio et al., 2015).  
 
2.3.2.2 Metabolism of AFB1 
The bioactivation and detoxification of AFB1 in the body requires the activity of metabolizing 
enzymes (Figure 2.3). The CYP family is responsible for AFB1 bioactivation in the liver and 
lipoxygenases (LOX) and prostaglandin H synthase (PHS) are necessary for its biotransformation 
in the lung (Bbosa et al., 2013c, Deng et al., 2018). In poultry species the CYP2A6, CYP3A37, 
CYP1A1 and CYP1A5 are responsible for AFB1 bioactivation. Human CYP1A2 and CYP3A4 in 
the liver and CYP3A5 and CYP2B6 in the kidney play a role in the activation of AFB1 to a reactive 
toxic metabolite, aflatoxin B1-8,9-epoxide (AFBO) which facilitates its carcinogenic and cytotoxic 
effects (Knights et al., 2013, Liu and Wang, 2016).  
 
The conjugation of AFBO with GSH is a major route of detoxification leading to the excretion of 
the epoxide (Figure 2.5). Conjugation with GSH disrupts AFBO ability to bind to DNA and 
proteins forming an inert metabolite that is then converted to a mercapturic acid adduct through a 
series of enzymatic reactions including -glutamyl transpeptidase (GGT), dipeptidase (PEP) and 
N-acetyltransferase (NAT) and then can be excreted in urine (Rushing and Selim, 2018). This is 
an important pathway of for detoxification of AFB1 as a carcinogen even though depletion of GSH 
results in high levels of reactive oxygen species (ROS) causing oxidative damage (Marchese et al., 
2018, Rushing and Selim, 2018).  
 
 
 
Figure 2.5 : The biotransformation of AFB1  by enzymes CYP3A4/3A5 to form a reactive AFB1-8,9-
epoxide with a functional group denoted in red. The epoxide can  conjugate with GSH in a reaction catalysed 
by the enzyme glutathione-S-transferase (GST) for protective effects forming an AFB1 glutathione 
conjugate that can be detoxified thus minimizing the toxicity of AFB1 (Stewart et al., 1999).  
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2.3.3 Biochemical effects of AFBO 
 
2.3.3.1 DNA  
The detrimental effects of AFB1 have been attributed to the metabolism of this toxin. The reactive 
metabolite AFBO reacts with the N7 atom of guanine and forms a pro-mutagenic DNA adduct 
aflatoxin-N7-guanine which can cause gene mutations resulting in damage to DNA (Figure 2.6) 
(Bbosa et al., 2013c).The most common mutation found in human hepatocytes exposed to AFB1 is 
a G-T transversion on codon 249 of the p53 gene. The tumour suppressor protein p53 regulates 
various cellular functions including DNA repair, cell cycle progression and apoptosis (Marchese 
et al., 2018, Rushing and Selim, 2018). Many cancers including hepatocellular carcinoma (HCC) 
possess mutations in p53 which is thought to alter the tumour suppressive functions of p53 leading 
to formation of cancerous cells (Marchese et al., 2018). Epidemiological studies in humans in 
aflatoxin risk regions have revealed a positive correlation between p53 mutations and aflatoxin 
presence in HCC patients, giving strong evidence that AFB1 exposure results in HCC development 
in humans by mutating p53 (Szymańska et al., 2004, Kirk et al., 2005, Rushing and Selim, 2018). 
In addition, it has been reported that AFBO exerts an inhibitory effect on the biological processes 
including DNA synthesis, DNA repair, DNA-dependent RNA synthesis and protein synthesis 
(Deng et al., 2018, Marchese et al., 2018). 
 
 
 
Figure 2.6 : The reactive metabolite AFBO can react with guanine bases at the N7 atom in DNA to form 
the AFB1-N7-dG adduct that can potentially cause gene mutations resulting in DNA damage and can be the 
onset of many diseases (Stewart et al., 1999). 
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2.3.3.2 Proteins  
The  reactive metabolite AFBO has a highly unstable nature, which can cause the metabolite to 
spontaneously hydrolyse before binding to any macromolecules resulting in the formation of AFB1-
dihydrodiol which is in equilibrium with an open ring aldehyde called AFB1 aldehyde (Figure 2.7) 
(Roebuck et al., 2009, Bbosa et al., 2013c, Rushing and Selim, 2018). The AFB1 aldehyde can 
form Schiff base derived adducts in cellular proteins by covalently binding to the N-termini and  
lysine side chains forming AFB1 lysine adducts (AFB1-lys) and these proteins adducts have been 
implicated in AFB1 acute toxicity (Figure 2.7) (Roebuck et al., 2009, Rushing and Selim, 2018). 
The AFB1 aldehyde can undergo further metabolism by aflatoxin aldehyde reductase (AFAR) into 
AFB1 dialcohol eliminating its protein binding potential (Figure 2.7). Protein binding of AFBO 
and AFB1 aldehyde usually occurs on serum albumin, which has a half of approximately 20 days 
making it a reliable biomarker of AFB1 exposure (Rushing and Selim, 2018). 
 
Figure 2.7 : The mechanism by which the AFB1 epoxide enhances its biochemical effects on proteins by 
binding to lysine residues resulting in adduct formation, hence protein binding. The reduction enzymatic 
activity of aflatoxin-aldehyde reductase (AFAR) reducing AFB1- diahydrodiol to AFB1-dialcohol limits 
binding of the epoxide to proteins reducing it effects (Prepared by author). 
 
2.3.3.3 Lipids  
The accumulation of aflatoxins and its metabolites have been reported to induce lipid peroxidation 
in cells resulting in cell membrane damage (Bbosa et al., 2013c). Lipid peroxidation is described 
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as a process in which oxidants such as free radicals attack lipids comprising of carbon-carbon 
double bond(s) especially polyunsaturated fatty acids (PUFAs) (Ayala et al., 2014). This process 
involves the abstraction of hydrogen from a carbon with an insertion of oxygen resulting in lipid 
peroxyl radicals and hydroperoxides (Figure 2.8). In response to lipid peroxidation cells may 
promote survival or induce cell death. Under minimal lipid peroxidation rates cells, stimulate an 
antioxidant response for their maintenance and survival whereas at high lipid peroxidation rates  
the extent of oxidative damage overwhelms the cells repair capacity and cells may activate cell 
death signalling pathways (Ayala et al., 2014). Lipid peroxidation can result in the formation of 
many oxidation products including malondialdehyde (MDA), lipid hydroperoxides (LOOH), 
propanal and 4-hydroxynonenal (4-HNE) (Ayala et al., 2014). 
 
Figure 2.8 : The peroxidation of lipids in cells adapted from (Basu, 2007). 
 
The accumulation of the AFBO metabolite depletes glutathione, an antioxidant which is used as 
part of the detoxification process. The depletion of GSH leads to the accumulation of abnormally 
high concentration of free radicals in cells,  thus affecting cell membrane integrity (Bbosa et al., 
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2013b, Rushing and Selim, 2018).  Deficiency in GSH also enhances damage to essential cellular 
macromolecules including DNA and proteins (Bbosa et al., 2013b, Rushing and Selim, 2018). 
 
2.4 OXIDATIVE STRESS 
Humans and animals require energy to survive. The production of this energy is dependent on 
mitochondria which utilise the oxygen (O2) breathed in to produce energy in the form of ATP. To 
facilitate this activity, mitochondria have an electron transport chain (ETC) that passes electrons 
through a series of complexes, generating a hydrogen gradient that culminates in the reduction of 
O2 to ATP and water (Yong et al., 2019). This activity can result in the production of highly reactive 
metabolites known as free radicals within cells. Free radical production can induce oxidative stress 
when there is an imbalance between the production of reactive oxygen species (ROS) and the 
biological ability of antioxidants to clear the toxicity of the reactive metabolites (Di Meo et al., 
2016). This imbalance has been considered as an important molecular mechanism underlying cell 
injury that can result in irreparable oxidative injury and even cell death when it gets beyond control.  
 
2.4.1 Production of free radicals 
Studies have reported that there are two sources of ROS production; the endogenous such as 
oxygen leakage from the mitochondria during oxidative phosphorylation and exogenous including 
xenobiotics, chlorinated compounds, pathogens and inflammatory cytokines. The major 
endogenous ROS in living cells is the superoxide anion radical (O2-). Other ROS derived from the 
metabolism of molecular oxygen include singlet oxygen (O2), hydrogen peroxide (H2O2), 
peroxynitrite (ONOO-) and the highly reactive hydroxyl radical (·OH) (Figure 2.9) (Ling and Kuo, 
2018). Deleterious effects of oxygen result from its metabolic reduction to these highly reactive 
and toxic species.  
 
Reactive oxygen species are not always harmful metabolic by-products; they normally exist in all 
aerobic cells as mediators in many biological processes (Liu and Wang, 2016). When tightly 
regulated they can act as intracellular signalling molecules,  but a critical imbalance resulting from 
excess ROS production, antioxidant depletion or both can result in oxidative stress (Liu and Wang, 
2016).  
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Figure 2.9 : The production of ROS as a consequence of mitochondrial respiration (Kutschera and Niklas, 
2013). 
 
2.4.2 Antioxidant response 
Redox balance is required in cells, therefore an antioxidant defence system consisting of 
antioxidant enzymes is provided. The expression of antioxidant enzymes such as superoxide 
dismutase (SOD), catalase, and glutathione peroxidase (GPx) is tightly controlled by antioxidant 
response elements (AREs) and activated nuclear related factor-2 (Nrf-2), which is a redox sensitive 
transcription factor (Liu and Wang, 2016). The Nrf-2 promotes the induction of target genes such 
as glutathione-S-transferases (GST), glutathione reductases (GR) and GPx that are responsible for 
cell survival. When cells are subjected to ROS, Nrf-2 is activated as an adaptive response to protect 
cells from impending oxidative stress; it translocates to the nucleus where it transactivates genes 
that encode different antioxidant enzymes, which act to maintain cell homeostasis (Liu and Wang, 
2016). 
 
Superoxides are scavenged by SOD in a dismutation reaction that converts O2
- to H2O2 and O2 
(Figure 2.9, 2.10). Superoxide anions can also react with nitric oxide (NO) to produce ONOO-, the 
instigator of nitrosative stress (Figure 2.10). Hydrogen peroxide may be converted into water by 
the enzymes catalase or GPx and inductive changes or variability in the expression of these 
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enzymes can influence cellular redox potential (Figure 2.10) (Ling and Kuo, 2018). However, Nrf-
2 activation by ROS limits the capacity of cells to escape from injury because they also stimulate 
cell death signals leading to the execution of apoptosis (Liu and Wang, 2016). 
 
 
 
Figure 2.10 : The  scavenging and protective effects of antioxidants against ROS (Sznarkowska et al., 2017)  
 
It has been reported that CYP is a key enzymatic complex in the mitochondria associated with 
electron leakage, which is one of the important sources of intracellular ROS generation, thus 
implicating CYP enzymes in the production of ROS. Therefore, bioactivation of AFB1 by the CYP 
enzymes results in an increase in ROS production and the generated reactive species can result in 
lipid peroxidation of membranes and oxidative modification of proteins and DNA (Liu and Wang, 
2016). In addition, the accumulation of AFB1 and its metabolites in the body especially the AFBO 
depletes the GSH which is an important antioxidant that prevents cellular damage caused by ROS 
(Carvajal-Moreno, 2015). The depletion of GSH is therefore due to the formation of high amounts 
of epoxides and ROS in the body resulting in oxidative stress. The expression of GSH could 
increase protection  against AFB1-induced hepatocarcinogenesis (Liu and Wang, 2016).  
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Excessive ROS can attack lipids, protein and DNA, and induce oxidative injury that inactivates 
biological activity of these important cellular macromolecules (Di Meo et al., 2016, Elwahab, 
2017). The increase in ROS also reduces the cleaning ability of antioxidants such as SOD, GPx, 
glutathione reductase (GR) and non-enzymatic antioxidants like GSH resulting in oxidative stress 
(Elwahab, 2017). 
 
2.5 MECHANISMS OF CELL DEATH 
2.5.1 Apoptosis 
Apoptosis is a form of programmed cell death that occurs in multicellular organisms in balance 
with cell division. It is a highly regulated process that serves to eliminate unwanted /unnecessary 
cells. Apoptosis is carried out by a family of protease enzymes called caspases (cysteine aspartyl-
specific proteases) which cleave target proteins; their activity is essential for successful apoptosis 
(Pfeffer and Singh, 2018). Apoptosis occurs in two main pathways, viz. the intrinsic or 
mitochondrial pathway, and the extrinsic or death receptor pathway (Figure 2.6). These pathways 
are linked and the molecules used in one pathway can influence the other (Li et al., 2018). 
 
The extrinsic pathway of apoptosis occurs when a death signal binds to a death receptor; the known 
death receptors are TNF receptor (TNFR1) and a related protein called Fas (CD95), and their 
ligands are TNF ligand (TNFL) and Fas ligand (FasL) respectively (Figure 2.11). The death 
receptors contain intracellular death domains that recruit adaptor proteins, a TNF associated death 
domain (TRADD) and a Fas-associated death domain (FADD), as well as a cysteine aspartate 
protease like caspase 8. Binding of the ligand to the death receptor results in the activation of death 
domains and recruitment of adaptor proteins forming a death inducing signalling index (DISC) 
complex (Liu and Wang, 2016). The DISC complex initiates the activation of pro-caspase 8 to 
caspase 8, an initiator caspase that initiates apoptosis by cleaving other downstream executioner 
caspases (Figure 2.11) (Pfeffer and Singh, 2018). 
 
The intrinsic pathway results when a signal received from signalling molecules such as ataxia 
telangiectasia mutated (ATM) and check point kinase (CHK) activate the p53 gene.  p53 recruits 
proteins such as Bax/Bak to increase mitochondrial permeability by forming pores that allow the 
release of pro-apoptotic molecules including cytochrome c into the cytosol (Pfeffer and Singh, 
2018). The intrinsic pathway can also be initiated by caspase 8 when it cleaves Bid to t-Bid, thus 
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facilitating Bax activation (Figure 2.11). Cytochrome c binds to Apaf-1 in the cytosol and forms a 
wheel-like heptamer that contains caspase activation and recruitment domains (CARDs); pro-
caspase 9 binds its respective CARD domain and becomes activated into caspase 9 (Figure 2.11).  
 
Caspase 8 and caspase 9 are both able to cleave and activate pro-caspase 3 to caspase 3, an effector 
caspase (Figure 2.11). Caspase 3 directs the changes cell morphology that are hallmarks of 
apoptosis, including cell shrinkage, membrane blebbing, DNA fragmentation and condensation, 
and formation of apoptotic bodies that are removed by phagocytes (Pfeffer and Singh, 2018). 
 
 
 
Figure 2.11 : The intrinsic and extrinsic pathways of apoptosis (Rampal et al., 2012) 
 
Apoptosis is a self-managed operation that kills damaged cells and maintains minimal damage to 
surrounding tissues. Defective apoptotic processes have been reported in various diseases and it 
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has been reported that AFB1 was able to induce apoptosis in hepatocytes, bone marrow, lung cells 
or human bronchial epithelial cells (Chen et al., 2016). 
 
2.5.2 Necrosis 
Necrosis is a form of cell death that is considered accidental, unprogrammed or due to cell injury 
and occurs when ATP is depleted (Jog and Caricchio, 2014). This form of cell death results from 
different stimuli such as cellular stress, heat, osmotic shock, high concentrations of H2O2 and toxin 
exposure that initiate changes at the cellular level. Under pathological conditions an increase in 
ROS produced by the mitochondria can induce damage in biomolecules which can lead cells 
towards necrosis. 
 
The morphological characteristics of necrosis include swelling of the cell membrane, chromatin 
condensation and irregular DNA degradation (Figure 2.12) (Escobar et al., 2015). The increased 
cellular swelling results in the breakdown of plasma membranes which releases cytoplasmic 
contents into the extracellular space (Figure 2.12). The necrotic process occurs in the absence of 
phagocytosis and its final stage is mainly characterized by the loss of cell membrane integrity 
(Escobar et al., 2015). 
 
 
 
Figure 2.12 : The morphological characteristics of necrotic cell death (Escobar et al., 2015). 
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2.6 EFFECTS OF AFB1 
2.6.1   Multiple organs and cell lines  
Aflatoxin B1 (AFB1) has reported to affect several body organs including the liver, brain, heart 
skeletal muscle and different body systems. AFB1 exposure is associated with enlargement of the 
liver, congestion of the liver parenchyma, necrosis of hepatocytes and liver cancer (Hussain et al., 
2008). It has also been reported that AFB1 induced a decrease in protein content in the liver, heart, 
and skeletal muscle in animals due to its ability to inhibit metabolic systems such as protein 
synthesis thus leading to liver and heart damage (Wangikar et al., 2005). People working in food 
industries get exposed to AFB1 when they inhale contaminated dust during processing; this may 
lead to lung cancer (Van Vleet et al., 2002, Zhang et al., 2014). Studies with experimental animals 
have demonstrated that AFB1 induces pulmonary adenomas and tumours in both the peripheral and 
central nervous system (Coulombe Jr, 1994). AFB1 is also known to alter neurotransmitters and 
their precursors in mouse brains (Coulombe Jr, 1994).  
 
It has been reported that the consumption of AFB1 diets induced an increase in MDA levels and a 
reduction in GSH levels resulting in oxidative stress in the spleen of broilers, and that excessive 
apoptosis in splenic lymphocytes correlated with an increase in oxidative stress (Chen et al., 2016), 
Furthermore, (Yilmaz et al., 2018) also showed that AFB1 significantly decreased antioxidant 
activity such as glutathione peroxidase (GPx), GSH, catalases, superoxide dismutase (SOD) and 
glucose-6-phosphate dehydrogenase (G6PD) in the heart and kidney tissues of AFB1-treated rats 
which can lead to cardiac and renal damage (Yilmaz et al., 2018). In a comparative study, (Qureshi 
et al., 2015) revealed that AFB1 affected cell viability of human umbilical vein endothelial cells 
(HUVEC), human brain microvascular endothelial cells (HBMEC) as well as immortalized 
epithelial cells of human hepatocellular carcinoma (Huh7). It was also observed that at high AFB1 
concentrations, an 85% cell death rate was induced in HBMEC and only 22% in HUVEC, while 
no cell death was observed in Huh7. It was further revealed that low concentrations of AFB1 
induced DNA adduct formation in HBMECs, while no adduct formation was observed at low and 
high AFB1 concentrations in HUVECs (Qureshi et al., 2015). However, high concentrations of 
AFB1 induced DNA adduct formation in Huh7. This showed that AFB1 was converted to its 
reactive metabolite AFBO in HBMECs and Huh7, which had varying activities of 
biotransformation enzymes. In addition to the cytotoxic effects of AFB1 in cell cultures, Al Ouqaili 
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(2018)  also showed that high AFB1 concentrations inhibited growth of hematopoietic stem cells 
(HSCs) hence decreasing viability of treated cells (Al-Ouqaili, 2018).  
 
While AFB1 mainly targets the liver, it was recently reported to induce myocardial toxicity in rats. 
Ge et al. (2017) revealed that the consumption of AFB1 by rats lead to disruption of the 
mitochondrial membrane and disorganisation of the cristae, an indication of mitochondrial damage 
(Ge et al., 2017). It was found that myocardial apoptosis was significantly higher after treatment 
with AFB1 relative to the control as the activities of caspase 3, Bax and BCl2 were upregulated in 
the cardiac tissue. Due to AFB1 lipophilicity, its distribution in blood and the excretion by kidney, 
the kidney may also be susceptible to its toxic effects. Various studies have also reported that AFB1 
is nephrotoxic and induces renal damage in rats (Abdel-Hamid and Firgany, 2015, Asa et al., 2018, 
Yilmaz et al., 2018). 
 
2.7 TOXIC EFFECTS ON THE KIDNEY 
2.7.1 Kidney structure and function 
The kidneys are a pair of bean-shaped organs located on either side of the spine, below the ribs and 
behind the belly that play a vital role in the body because they remove wastes and excess fluid from 
the body. The kidneys also remove acid produced by cells of the body and maintain a healthy 
balance of water, salts and minerals such as calcium, sodium, and potassium in the blood  
(Lawrence et al., 2018). Without this balance, heart, muscles, nerves and other tissues in the body 
won’t be able to function properly, as all blood in the body passes through the kidney properly. 
Blood enters the kidney, waste gets removed and salt, water and minerals are adjusted if necessary. 
The filtered blood is transferred to different parts of the body and waste is turned into urine, which 
collects in the pelvis, a structure that drains down a tube called the ureter to the bladder. 
 
The most important part of each kidney are the nephrons (Figure 2.13) (Lawrence et al., 2018). 
Each kidney is made up of approximately 1 million nephrons. Nephrons are tiny filtering units and 
each nephron includes a filter called a glomerulus and a tubule (Figure 2.13). Nephrons work in a 
two-step process; the glomerulus filters blood and the tubule restore the needed substances to the 
blood and removes waste (Figure 2.13). If blood stops flowing into a kidney that could result in 
kidney failure (Lawrence et al., 2018).  
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Figure 2.13 : The structure of a human kidney adapted from  (Glassock and Rule, 2016). 
Due to their critical role as an excretory organ, the kidney receives a disproportionate percentage 
of blood flow, thus exposing the kidneys to high concentrations of circulating toxins. In addition, 
the workload imposed increases their nutrient, oxygen and energy requirements (Moosa et al., 
2015). The kidneys not only facilitate many vital functions in the body, but it has been reported 
that they possess a significant metabolizing capacity. The kidney expresses a variety of enzymes 
involved in metabolism including CYP2B6, CYP3A4, CYP3A5, CYP4A11, CYP4F2, CYP4F8, 
CYP4F11 and CYP4F12 (Knights et al., 2013). 
 
2.7.2 The Human embryonic kidney (Hek293) cell line 
The Hek 293 cell line was derived from primary human embryonic kidney cells that were obtained 
from a health aborted foetus and is an adherent cell line. The Hek 293 cell line is understood to be 
of epithelial origin and has been transformed with sheared  adenovirus 5 DNA (Stepanenko and 
Dmitrenko, 2015). Due to its high metabolic nature, easy reproduction and maintenance makes its 
one of the most used cell lines in biotechnology and cell biology studies. These cells are used as 
models of human renal cells in invitro studies (Stepanenko and Dmitrenko, 2015).  
  
2.7.3 Effects of AFB1 on the kidney 
Different parts of the nephron are exposed to aflatoxins before they are excreted, thus AFB1 and 
its metabolites may lead to nephrotoxicity (Coulombe Jr, 1994, Sharma et al., 2011, Bbosa et al., 
2013a). The reduction in protein induced by aflatoxin has been attributed to increased necrosis of 
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the kidney (Sharma et al., 2011, Bbosa et al., 2013a). AFB1 has been implicated in kidney tumour 
formation in experimental animals and a mixture of aflatoxin B and aflatoxin G was reported to 
cause approximately 80% of renal and hepatic tumours in hamsters (Coulombe Jr, 1994, Bbosa et 
al., 2013a). There were also renal lesions with features of megalocytosis in the proximal renal 
tubes. 
 
In Africa, AFB1 exposure lead to the development of fatty and hemorrhagic kidney syndrome 
abnormal development of glomerular epithelial cells, thickening of the glomerular basement 
membrane and degenerative changes in renal tubular cells in birds (Hussain et al., 2008, Bbosa et 
al., 2013a). In other animals, a reduction in the glomerular filtration rate, glucose reabsorption and 
tubular transport of electrolytes and organic anions, reduced glutamate-oxaloacetate and pyruvate 
transaminases was observed in rats. These changes were attributed to aflatoxins and other 
metabolites as well as the produced ROS. In cultured kidney cell lines, AFB1 was implicated in the 
induction of  aggregated and condensed chromatin, mitochondrial degeneration and loss of 
microvilli  (Bbosa et al., 2013a). 
 
The reported information clarifies that AFB1 poses a great challenge to human health and even 
though the main target organ for this toxin is the liver, it can also be toxic to other parts of the body 
including the kidney which is one of the important body organs. Studies have reported the effects 
of AFB1 on other organ systems like the liver, and studies have been done on mouse/rat kidneys 
but a gap in literature came to light as studies on the effects of AFB1 in the human kidney have not 
been have been reported. The methodology employed to evaluate the effects of AFB1 on human 
embryonic kidney (Hek293) cells will be discussed in the following chapter.  
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CHAPTER 3 : MATERIALS AND METHODS  
 
This chapter describes the protocol principles and procedures followed to evaluate the effects of 
aflatoxin B1 (AFB1) on Hek293 cells. It provides information on the materials used for this 
particular study, how the cells were maintained prior to treatment and how cell treatments were 
prepared.  The instruments used to collect data and statistical tests used to analyse the data collected 
are also described. 
 
3.1  MATERIALS  
 
The mycotoxin AFB1 was purchased from Sigma Aldrich (Johannesburg South Africa (S.A)), the 
human embryonic kidney (Hek293) cell line was purchased from Highveld Biological in 
Johannesburg, South Africa (SA). Tissue culture reagents were purchased from Whitehead 
Scientific (Johannesburg, SA). The methylthiazol tetrazolium (MTT) salt, phosphate buffered 
saline (PBS) tablets were purchased from Capital Laboratory Supplies, SA. Reagents for the 
thiobarbituric acid (TBA) reactive substances assay (TBARS) and nitric oxide synthase (NOS) 
assay were procured from Capital Laboratory Supplies, SA. The lactate dehydrogenase (LDH) 
cytotoxicity detection kit was purchased from Roche (Manheim, Germany). DNA fragmentation 
kit was purchased from Thermo fisher Scientific (Johannesburg, S.A) All western blotting reagents 
were purchased from Bio-Rad (Hercules, CA). The Cell Signalling Technology (CST) antibodies 
and Promega luminometry kits were purchased from Anatech (SA).Other reagents such as salts 
and solvents used for preparation of buffers were purchased from Merck (Darmstadt, Germany). 
 
3.2  CELL CULTURE 
3.2.1 Background 
Cell culture is a technique in which cells are grown outside of the body in an artificial environment 
that mimics physiological conditions (Jedrzejczak-Silicka, 2017). Under appropriate conditions of 
temperature, pH, a solid support, fluid medium and aseptic conditions the cells can live and grow 
abundantly. This technique was developed by an American embryologist Ross Granville Harrison 
(1870-1959) in the first decade of the 20th century and was first practised in 1907 at the Yale 
university (Jedrzejczak-Silicka, 2017). The development of cell culture techniques shed light to 
many possibilities in cell and tissue culture and as has been used as a tool in many applications. 
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3.2.2 Protocol 
A vial of cryopreserved Hek293 cells was thawed at 37˚C and reconstituted in a 25 cm3 flask, in 
10 ml of complete culture medium (CCM) comprising of Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% foetal calf serum (FCS), 1% L-glutamine, 1% penicillin 
streptomycin fungizone and 1.25 mM HEPES. The flask was placed in an incubator containing 5% 
CO2 at 37˚C for 4 hours (4hrs). After 4hrs the CCM was discarded, the flask was replenished with 
5 ml of CCM and incubated overnight (5% CO2, 37
oC). The cells were maintained and monitored, 
the CCM was changed frequently until cells reached confluency. Confluent cells were counted 
using the trypan blue method for use in consecutive assays.   
 
3.3  PREPARATION OF THE TREATMENTS 
The aflatoxin B1 stock solution (640 µM) was prepared by dissolving 1 mg AFB1 5 ml of CCM. 
The AFB1 stock was stored at 4˚C and diluted in CCM to obtain different AFB1 concentrations 
required for the different treatments in subsequent assays. Untreated cells served as the control in 
all experiments. 
 
3.4  MTT ASSAY 
 
3.4.1  Background 
The MTT (3- (4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide) assay is a colorimetric 
assay used to evaluate cell viability or cytotoxicity (Adan et al., 2016, Riss et al., 2016). The 
determination of cell viability is principally guided by ascertaining mitochondrial function of cells 
by measuring the activity of mitochondrial enzymes such as succinate dehydrogenase (Adan et al., 
2016, Riss et al., 2016). The MTT salt is a water-soluble tetrazolium dye that is reduced to a water 
insoluble purple formazan product in metabolically active cells using succinate dehydrogenase and 
NADH (Figure 3.1) (Adan et al., 2016, Riss et al., 2016). The intensity of the formazan product is 
directly proportional to the number of viable cells which can be measured at a specific wavelength 
using a spectrophotometer.  
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Figure 3.1 : The reduction of the yellow tetrazolium salt to purple formazan by metabolic active cells 
(Prepared by author). 
 
3.4.2  Protocol 
The toxicity and half inhibitory concentration of AFB1 was evaluated using the MTT assay. The 
Hek293 cells were seeded at a density of 20000 cell/well (200 µl) in a 96 well microtiter plate in 
triplicates and incubated overnight (5% CO2, 37
oC) for attachment. Treatments with different AFB1 
concentrations (0-100 µM) were prepared and the cells were treated with 300 µl of each treatment 
in triplicates and incubated (5% CO2, 37
˚C) for 24hrs.  
 
Following incubation, the treatments were discarded, and the cells were incubated (37˚C, 5% CO2) 
with 120 µl/ well of the MTT salt solution (4mg in 800 µl of 0.1M PBS and 4 ml of CCM) for 4hrs. 
The MTT salt solution was replaced with 100µl of the solubilising agent dimethyl sulfoxide 
(DMSO) for 1 hr at 37oC to dissolve the formazan crystals. The absorbance of the samples was 
ascertained using the Bio-Tek µQuant plate reader (USA) at a wavelength of 570 nm and reference 
wavelength of 690 nm. The absorbance values were used to calculate % cell viability as 
follows: 
𝑎𝑣 𝑎𝑏𝑠 𝑜𝑓𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑎𝑣 𝑎𝑏𝑠 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
 𝑥 100. The half maximum inhibitory concentration (IC50) was obtained 
using GraphPad Prism v5.0 (GraphPad Software Inc., La Jolla, USA) by plotting a concentration 
response curve (log concentration vs cell viability of samples). The calculated IC50 was used to 
extrapolate a concentration lower (IC25) and one concentration higher (IC75) for use in subsequent 
assays. 
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3.5  ATP ASSAY  
 
3.5.1  Background 
 The main energy source for all cellular activities is ATP, a nucleotide triphosphate produced 
mainly by mitochondria in all living cells that functions to store and supply cells with energy when 
necessary (Yong et al., 2019). Mitochondrial toxicity and loss of membrane integrity impacts on 
the ability to synthesize ATP, the ATP levels of cells drastically decrease, and cells may die (Yong 
et al., 2019). 
 
The ATP assay is based on the luciferin and oxyluciferin reaction. During the reaction the enzyme 
luciferase catalyses the interaction between luciferin and oxygen to form oxyluciferin in the 
presence of Mg2+ and ATP, yielding a luminescent signal released in the form of light (Figure 3.2) 
which can be measured using a luminometer (Riss et al., 2016). Since ATP is necessary for the 
reaction, there is a linear relationship between the intensity of luminescent signal produced and 
ATP concentration (Adan et al., 2016, Riss et al., 2016).  
 
 
Figure 3.2 : Luciferase catalysed bioluminescence reaction in the presence magnesium ion (Mg2+) and ATP 
(Prepared by author). 
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3.5.2  Protocol  
The intracellular activity of ATP was quantified using the Promega Cell Titre-Glo® (#G7570) 
luminescent assay. The reagents were prepared according to the manufacturer’s instructions. 
Hek293 cells were plated in a 96 well white luminometer plate at volume of 20000 cells/well (200 
µl) and incubated overnight for adherence (5% CO2, 37˚C). The cells were then treated with 300µl 
of AFB1 concentrations (IC25, IC50, IC75) in duplicates for 24hrs, the untreated cells served as the 
control. Following treatment, the treatment media was discarded, and the cells were gently washed 
1x with 300 µl of 0.1 M PBS. The wells were replenished with 50 µl of 0.1 M PBS and 25 µl of 
Cell Titre-Glo® ATP reagent was added to each well. The plate was incubated at room temperature 
in the dark for 30 minutes. Luminescence was measured using a Modulus™ microplate 
luminometer (Turner Bio-Systems, Sunnyvale, California, USA) and data was expressed as relative 
light units (RLU).  
 
3.6  TBARS ASSAY 
 
3.6.1  Background 
Lipid peroxidation occurs when hydrogen atoms in PUFAs containing a single electron are 
removed by free radicals leaving behind an unpaired electron on the carbon atom. The molecule 
undergoes molecular rearrangement, followed by a reaction with O2 to generate a peroxyl radical. 
The peroxyl radicals may then attack membrane proteins, but are also capable of abstracting 
hydrogen atom from an adjacent fatty acid side chain thus propagating the chain of lipid 
peroxidation (Ayala et al., 2014). 
 
 Lipid peroxidation results in the formation of highly reactive and unstable lipid peroxides. The 
decomposition of these peroxides results in malondialdehyde (MDA) formation. This intermediate 
can be quantified following its reaction with thiobarbituric acid (TBA) (Zeb and Ullah, 2016). The 
reaction between MDA and thiobarbituric acid (TBA) results in the formation of a pink chromogen 
which can be detected using a spectrophotometer at 532nm (Figure 3.3). 
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Figure 3.3 : The principle of the TBARS assay showing that thiobarbituric acid (TBA) reacts with MDA in 
the presence of heat or acid to produce a coloured product that is proportional to lipid peroxidation levels in 
samples (Prepared by author).  
 
3.6.2  Protocol 
Treatment media (200 µl) from the control and treatments were added to four clean labelled glass 
test tubes. Two additional tubes were prepared; viz. the negative (200 µl CCM) and positive (199 
µl CCM + 1 µl MDA) controls. Each tube then received 200 µl of 2% and 7% phosphoric acid 
(H3PO4) each, followed by the addition of 400 µl of TBA/butylated hydroxytoluene (BHT) solution 
to every sample except the blank, which received 400 µl of 3 mM HCL. The tubes were briefly 
vortexed and the mixture in each tube was acidified by adding 200 µl of 1 M HCl. The tubes were 
boiled in a water bath for 15 minutes to allow for the hydrolysis of MDA adducts. The samples 
were left to cool to room temperature and 1500 µl of butanol was added to each tube. After 
vortexing each tube for 30 seconds, the tubes were allowed to stand so that samples can settle, and 
the two distinct phases were visualised.  Thereafter, 200 µl of the upper phase of each sample was 
pipetted in triplicate in a 96-well plate and the plate was read using Bio-Tek µQuant 
spectrophotometer at 532 nm, with a reference wavelength of 600 nm. The average of 3 replicates 
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was calculated and divided by the absorption coefficient, 156 mM-1 and multiplied by 1000 to 
determine the average concentration of MDA (µM).  
 
3.7  NITRIC OXIDE SYNTHASE (NOS) ASSAY 
 
3.7.1  Background 
Reactive nitrogen species are produced in all eukaryotic cells and are involved in the regulation of 
different physiological processes including differentiation, proliferation and metabolism. Nitric 
oxide (NO) is an unstable diatomic molecule which contains 1 unpaired electron which makes it a 
free radical. In mammalian cells, NO is formed from the enzymatic oxidation of L-arginine by 
nitric oxide synthases (Csonka et al., 2015). NO is a highly reactive molecule with a short half-life 
in biological environments. NO undergoes oxidative degradation to form stable metabolites 
products, nitrates (NO3
-) and nitrites (NO2
-) (Csonka et al., 2015). The NOS assay is based on the 
conversion of nitrate to nitrite by nitrate reductase, which is accomplished by vanadium chloride 
(VCl3) in this assay. This is followed by the acidic Griess reaction (Figure 3.4). Under acidic 
conditions, nitrates react with sulfanilimide (SULF) to form a diazo compound which couples with 
N-(1-naphthyl) ethylenediamine (NEDD) to form a purple chromophoric azo-derivative that can 
be measured at 540/690nm (Csonka et al., 2015). 
 
 
Figure 3.4 : 1. Nitrates (NO3-) and nitrites (NO2-) are formed nitric oxide (NO) in a reaction catalysed by 
the nitric oxide synthase (NOS) 2. The quantification of nitrites uses the GRIESS reaction to form a purple 
azo dye product that can be read spectrophotometrically at 540/690 nm (Prepared by author).  
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3.7.2  Protocol  
Sodium nitrate standards (0 - 200 µM) were prepared and the retained supernatants from treatments 
with different AFB1 concentrations, including the control samples were used. In a 96 well 
microtiter plate, 50 µl of samples/standard solution were pipetted into each well in duplicate. 
Sequentially, 50 µl of VCl3, 25 µl of SULF, 50 µl of NEDD were added in quick succession to 
each well, and the plate was incubated at 37˚C for 30 minutes. The absorbances were read using 
Bio-Tek µQuant plate reader at a wavelength of 540 nm and a reference wavelength of 690 nm. A 
standard curve was constructed to extrapolate sample nitrate concentrations. 
 
3.8  GSH ASSAY 
 
3.8.1  Background 
Reduced glutathione (GSH) is a tripeptide (L-γ-glutamyl-L-cysteinyl glycine) that serves as a key 
antioxidant to tissues and cells by providing a free thiol group (Salbitani et al., 2017). The reduced 
form (GSH) provides reducing equivalents for the glutathione peroxidase (GPx) catalysed 
reduction reaction of lipid peroxides to their corresponding alcohols and hydrogen peroxide to 
water. (Salbitani et al., 2017). During the GPx catalysed reaction the formation of a disulphide 
bond between two GSH molecules gives rise to oxidised glutathione (GSSG). The enzyme 
glutathione reductase (GR) recycles GSSG to GSH with simultaneous oxidation of NADPH2 
resulting in a decrease in GSH:GSSG ratio (Salbitani et al., 2017) . 
 
The quantification of GSH is based on a reaction catalysed by glutathione-S-transferase whereby 
a luciferin derivative is converted to luciferin in the presence of GSH. The light emitted is 
proportional to the amount of luciferin formed, which depends on the amount of GSH present 
(Elwahab, 2017). This makes the luminescent signal produced directly proportional to the amount 
of GSH present in a sample (Figure 3.5).  
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Figure 3.5 : Representation of luminometric measure of reduced glutathione (GSH) in samples (adapted 
from Promega protocols). 
 
3.8.2 Protocol 
The levels of intracellular GSH were quantified using the GSH-GloTM assay (#V6911, Promega, 
Madison, USA). Reagents were prepared according to the manufacturer’s guidelines. A volume of 
200 µl (20000 cells/well) were seeded into a white 96 well luminometer plate and left to attach 
overnight (5% CO2, 37˚C). Following attachment, 24hr treatments with different concentrations of 
AFB1 were done in duplicates and the plate was incubated at 37˚C in a humidified incubator 
containing 5% CO2. The treatment media was then removed and the in the wells were replenished 
with 50 µl of 0.1 M PBS. Thereafter, 25 µl of 1x GSH-Glo reagent was added to each well and the 
plate was incubated at room temperature, away from light. After 30 minutes, 50 µl of reconstituted 
luciferin detection reagent was added to each well and the plate was incubated in the dark for 15 
minutes. Luminescence was measured using the Modulus™ microplate luminometer (Turner Bio-
Systems, Sunnyvale, California, USA) and the data was presented as RLU. 
 
3.9  THE SINGLE CELL GEL ELECTROPHORESIS (SCGE) ASSAY 
 
3.9.1  Background 
The comet assay is commonly known as the single cell gel electrophoresis (SCGE) assay. It is a 
simple technique used to detect DNA fragmentation resulting from DNA damage in individual 
cells. The comet assay is based on the quantification of DNA fragments migrating from the nucleus 
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of the cell during electrophoresis (Nandhakumar et al., 2011). The comet assay was initially used 
to detect double stranded DNA breaks, however in 1988 Singh and his colleagues optimised the 
protocol in alkalinic conditions thus allowing for the detection of DNA single strand breaks. The 
alkaline comet assay involved embedding cells in agarose gel on a microscopic slide and immersing 
the slides in lysis solution. The undamaged DNA in the nucleus remains intact within the comet 
head and does not migrate. However, when DNA is damaged the damaged the DNA strands unwind 
and electrophoretically migrates out of the nucleus into the agarose suspension due to attraction of 
negatively charged DNA towards the positively charged anode and yield a comet tail 
(Nandhakumar et al., 2011). Jointly, the DNA tail and undamaged DNA resemble a comet (Figure 
3.6). The longer and brighter the comets tails become, the more extensive is the damage to DNA 
(Nandhakumar et al., 2011). 
 
 
 
Figure 3.6 : Schematic representation of the SCGE assay procedure (Prepared by author). 
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3.9.2 Protocol 
The comet/SCGE assay was used to detect DNA fragmentation in AFB1-treated Hek293 cells. 
Slides with frosted ends were used and labelled in duplicates for each treatment (C, IC25, IC50, 
IC75). Resuspended control and treated Hek293 cells were encompassed in 1% low melting point 
agarose (LMPA) sandwiched between a base layer comprising 2% LMPA and a top layer 
comprising 1% LMPA as each slide consisted of 3 gel layers. For the first gel layer, 800 µl of 2% 
LMPA was pipetted onto each slide, covered with a coverslip and left to set at 4°C for 10 minutes. 
The coverslip was removed and the second layer consisting of cell suspension (20000 cells in 400 
µl of 1% LMPA and 1 µl gel red) was pipetted onto the slide, overlayed with a coverslip and left 
to set at 4°C for 10 minutes. Following removal of the coverslip, the third layer consisting of 400 
µl of 1% LMPA was added, covered with a coverslip and left to set at 4°C for 10 minutes.  
 
After all the layers were set the slides were immersed in cell lysis solution that was prepared fresh 
beforehand (100 mM EDTA, 2.5 M NaCl, 1% Triton X-100, 10% DMSO, and 10 mM Tris (pH 
10) for an hour at 4°C. The slides were then allowed to equilibrate by immersing them in 
electrophoresis buffer (1mM Na2EDTA and 300 mM NaOH, pH 13) for 20 minutes preceding 
electrophoresis (25V, 35 minutes at 37oC). The electrophoresed gels were rinsed 3 times with 
neutralising buffer (0.4 M Tris, pH 7.4) at 5-minute time intervals. The slides were then viewed 
under a under a fluorescent microscope [Olympus IXSI inverted microscope] with 510-560nm 
excitation and 590nm emission filters.  Images were captured using Soft imaging system (Life 
Science - ©Olympus Soft Imaging Solutions v5) and 50 measurements of comet-tail length in µm 
were done for each treatment. 
 
3.10  CASPASE ACTIVITY  
 
3.10.1  Background 
Cysteine aspartate proteases (caspases) are a family of protease enzymes that play an essential role 
in the initiation and execution of programmed cell death. Caspases are expressed in all cell types 
and are initially expressed as inactive zymogens and are only activated once an apoptotic signal is 
received (McIlwain et al., 2013). This assay is based on the cleavage of conjugated aminoluciferin 
by caspases (Figure 3.7). Upon release of aminoluciferin, it reacts with luciferase in the presence 
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of ATP and molecular oxygen generating a luminescent signal that is proportional to the levels of 
caspase activity present in cells (Figure 3.7) (McIlwain et al., 2013). 
 
 
Figure 3.7 : Representation of proteasomal cleavage of conjugated aminoluciferin to aminoluciferin thereby 
producing light as a product which is directly proportional to caspase activity (Prepared by author). 
 
3.10.2  Protocol  
The activity of caspases 3/7, 8 and 9 were assessed using the Promega Caspase-Glo® assay [ 
#G8090, #G8200, #G8210 (Madison, USA) ] respectively. The reagents were prepared according 
to the manufacturer’s directions. The cells were plated at a density of 20000/well in a 96-well white 
luminometer plate and incubated overnight (5% CO2, 37˚C) and were then treated in duplicates 
with 300 µl of various concentrations of AFB1 (IC25, IC50, IC75) for 24hrs with untreated cells 
serving as the control. Following treatment, the cells were rinsed gently with 300 µl of 0.1 M PBS. 
Thereafter, 50 µl of 0.1 M PBS and 25 µl of Caspase-Glo®-3/7reagent was added into each well. 
The plate was incubated away from light for 30 minutes at room temperature. This procedure was 
repeated for caspase-8 and caspase-9 respectively. Luminescence was detected using the 
Modulus™ microplate luminometer (Turner Bio-Systems, Sunnyvale, California, USA) and the 
data was expressed as RLU. 
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3.11  ANNEXIN V ASSAY 
 
3.11.1  Background 
The annexin V assay was used to quantify the percentage of cells that are actively undergoing 
apoptosis and necrotic cell death within the cell population. This assay is guided by the principle 
that normal cells express the membrane phospholipid phosphatidylserine (PS) on the inner 
membrane (Figure 3.8) (Lakshmanan and Batra, 2013). When cells are damaged or undergo 
apoptosis, PS is exposed by flipping from the inner membrane to the outer membrane. The exposed 
PS is recognised by annexin V (Lakshmanan and Batra, 2013). Damaged membranes allow for a 
fluorescent DNA binding dye to enter the cells; the fluorescence is indicative of cells undergoing 
necrosis (Figure 3.8). 
 
 
Figure 3.8 : The annexin V assay principle in the detection of apoptotic and necrotic cells (Prepared by 
author). 
 
3.11.2  Protocol 
Human embryonic kidney cells (Hek 293 cells) were seeded at a volume of 20000 cells/ml (200 
µl) in a 96-well white luminometer plate, and incubated overnight to adhere (5% CO2, 37˚C).  The 
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2x detection reagent was prepared according to the manufacturer’s instructions; 1µl of 1000x 
annexin NanoBit,1 µl 1000x CaCl2, 1 µl 1000x Annexin V-SmBiT and 1µl 1000x Annexin V-
LgBiT. After incubation the cells were treated with different concentrations of AFB1 (C, IC25, IC50, 
IC75) for 24 hrs, then treatment media was removed, and the cells were washed gently with 300 µl 
of 0.1M PBS and replenished with 50 µl of 0.1M PBS, then 25 µl of the detection reagent was 
loaded into each well and the plate was incubated at room temperature protected from light for 30 
minutes. The luminescence and fluorescence were detected using Modulus™ microplate 
luminometer (Turner Biosystems) for apoptosis and necrosis and expressed in RLU and relative 
fluorescence units (RFU) respectively. 
 
3.12  LDH ASSAY  
 
3.12.1  Background 
Lactate dehydrogenase (LDH) is a stable, cytosolic enzyme found in cells that can be released from 
damaged cells (Fiume et al., 2014). When cell viability decreases, an increase in plasma membrane 
leakage occurs resulting in the release of LDH into the cell culture medium. The activity of LDH 
can be quantified using NADH produced during the conversion of lactate to pyruvate for the 
reduction of a yellow tetrazolium salt to form a red water-soluble formazan product (Figure 3.9) 
with quantifiable properties (Kumar et al., 2018). The amount of formazan produced is directly 
proportional to the amount of LDH in the culture which in turn is proportional to the number of 
damaged cells (Kumar et al., 2018). LDH release is considered as an early event in necrosis, but a 
late event in apoptosis. 
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Figure 3.9 : Representation of LDH release from a damaged cell and its conversation to measurable red 
formazan by enzyme diaphorase (Prepared by author).  
 
3.12.2 Protocol 
Hek293 cells were treated with various concentrations of AFB1 and the treatment supernatants were 
retained in eppendorf tubes labelled according to the different AFB1 treatments. In a 96 well plate, 
100 µl of the positive control (CCM only) and treatment supernatants (C, IC25, IC50, IC75) were 
pipetted into each well, followed by the addition of 50 µl of the reaction mix (25 µl blue cap 
catalyst, 0.563 ml LDH reagent- 2). The plate was incubated in the dark at 37˚C for 30 minutes. 
Following incubation, 25 µl of stop solution was added and the absorbances were read at 490/690 
using a Bio-Tek µQuant plate reader.  
 
3.13  WESTERN BLOTTING  
 
3.13.1  Background 
Western blotting is a technique used for the isolation and quantification of proteins in biological 
samples. This is achieved by separating proteins through a gel and allowing them to migrate under 
the influence of and electric field (Figure 3.10) (Taylor and Posch, 2014). The rate of migration is 
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based on their shape and molecular mass. The proteins are transferred to a nitrocellulose membrane 
which is incubated with specific antibodies that bind to the protein of interest (Figure 3.10, 3.11, 
3.12). The unbound antibody is washed off leaving only the bound antibody to the protein of 
interest (Taylor and Posch, 2014). Chemiluminescence is then used to detect the bound antibodies. 
Antibodies only bind to the protein of interest and only one band is visible. The thickness of the 
band corresponds to the amount of protein present.  
 
 
 
Figure 3.10 : Short overview presentation of the western blotting procedure (Prepared by author).  
 
3.13.2 Protein isolation  
Flasks of Hek293 cells were treated with IC25, IC50, IC75 concentrations of AFB1 and the untreated 
flask served as the control. CytobusterTM (Roche, Johannesburg, SA) reagent supplemented with 
protease and phosphatase inhibitors as per manufacture’s guidelines was used for the isolation of 
proteins from cells. The treated cells were washed once with 5 ml of 0.1 M PBS and 300 µl of the 
cytobuster reagent was added to each flask, then the flasks were left on ice for 15 minutes. The 
cells were scraped and transferred to 1.5 ml eppendorf tubes and centrifuged (2000 rpm, 4°C, 5 
minutes) for the separation of pellet and crude protein. After centrifugation the supernatant was 
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transferred into an eppendorf tube and was used for protein quantification using the bicinchoninic 
acid assay (BCA) assay. 
 
3.13.3 Protein quantification and sample preparation  
Bovine serum albumin (BSA) standards were prepared (0-1 mg/ml) and 25 µl per standard 
solution/sample was pipetted into a 96 well plate in duplicate. The BCA working solution was 
prepared (198 µl BCA:4 µl CuSO4)) and 200 µl of this solution was added to each well and the 
plate was incubated at 37˚C, away from light for 30 minutes. Following incubation, the absorbances 
were read on a Bio-Tek spectrophotometer (USA) at 562 nm and a standard curve was constructed. 
Sample protein concentrations were calculated, and standardised to 1 mg/ml. 
 
Standardized proteins were diluted in Laemli buffer (dH2O, 10% SDS, β-mercaptoethanol, 
glycerol, 0.5 M Tris, 1% bromophenol blue) and the samples were boiled for 5 minutes at 100˚C 
for denaturation of protein. 
 
3.13.4 SDS-PAGE and Transfer  
The denatured protein samples were separated on SDS-PAGE. A 10% resolving gel and 4% 
stacking gel [10% SDS, Tris, Bis-acrylamide, dH2O, 10% ammonium persulfate (APS), TEMED] 
was prepared and allowed to polymerise for an hour consecutively. Thereafter, the protein samples 
were subjected to an electric field (150 V) for 1 hr using a Bio-Rad compact power supplier. The 
electrophoresed gels were placed in transfer buffer (25 mM Tris, 192 mM glycine, 20% v/v 
methanol, pH 8.3) to allow equilibration between the gel and proteins. The proteins were then 
electro-transferred from the gel to a nitrocellulose membrane using a TransblotTM turbo 
programme, the gel was sandwiched between two fibre pads soaked in transfer buffer in a transblot 
cassette and subjected to a current of (25 V,1.0 Amp, 45 minutes). 
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Figure 3.11 : The transfer procedure of migrated proteins from SDS gel to a nitrocellulose membrane 
adapted from  creative diagnostics® western blot protocols. 
 
3.13.5 Immunoprobing  
Following transfer, the membranes were blocked with 5ml of 5% BSA in Tris buffered saline 
[dH20, NaCl, KCl, Tris-HCl (pH7.5)] with tween 20 (TTBS) and incubated on the shaker for 2hrs. 
It was necessary to block the membrane in order to prevent non-specific binding of antibodies. 
Thereafter the membranes were incubated with specific primary antibodies [SOD2 (#13141S), 
GPx1 (#3286S), Nrf-2 (#12721S), c-Parp (#9542S), catalase (#12980S), Hsp70 (#46477S), p53 
(#48818S), c-IAP (#7065S), Bax (#5023S), NF-κb (#8245S)] diluted in 5 % BSA,1:1000, for 1hour 
on shaker at room temperature, then overnight at 4˚C to allow for the binding of the antibody to its 
specific protein. Following overnight incubation, the membranes in primary antibodies were 
equilibrated to room temperature (1 hr on shaker), then the primary antibodies were removed, and 
membranes were subsequently washed 5 times (10 minutes) with TTBS to remove excess 
antibodies. This was followed by probing with horse radish peroxidase (HRP) conjugated 
secondary antibody [anti-mouse IgG (#7076S) for Hsp70and p53, anti-rabbit IgG (7074S) for 
SOD2, GPx1, Nrf-2, c-Parp, catalase, c-IAP, Bax and NF-κb)] diluted in 5ml of 5%BSA,1:2500, 
then incubation on shaker for 2 hrs. After incubation the membranes were washed 5 times with 
TTBS. For viewing, 150 µl of Clarity Western ECL Substrate (Bio-Rad) was added to the 
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membranes and images were captured using Molecular Imager® ChemidocTM XRS and Bio-Rad 
imaging system. 
 
 
 
Figure 3.12 : The binding of primary antibody to the target protein followed by the secondary antibody 
conjugated enzyme which allows for emission of a chemiluminescent detection signal adapted from (Elab 
science ® western blot protocols).  
 
To ensure the accuracy of results a housekeeping gene, β-actin was used to normalise the 
expression of proteins. The membranes were quenched after 1 wash with 5ml of H202 (30 minutes). 
Membranes were  washed again (1 wash with dH20 and 1 wash with TTBS; 5 minutes each) before 
blocking with 5 % BSA for 1hr.Thereafter, the membranes were reprobed with HRP-labelled anti-
human β-actin (1:5000 in 5 % BSA) for 1hr. The membranes were then washed 5x with TTBS and 
viewed as described above. The relative band density was calculated using band intensities of both 
the proteins of interest and the house keeping proteins and data was expressed as relative band 
density (RBI). 
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3.14  QUANTITATIVE PCR (qPCR) 
 
3.14.1  Background 
3.14.1.1 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR, Figure 3.13) is a technique used to amplify specific fragments of 
DNA in an enzyme reaction (Kralik and Ricchi, 2017).  PCR occurs in cycles and in every cycle 
the number of specific DNA sections is doubled resulting in an exponential amplification of target 
DNA (Kralik and Ricchi, 2017). Each PCR cycle comprises of steps including denaturation, primer 
annealing and primer extension. The initial step denatures or separates the double-stranded DNA 
template by heat (94˚C for 15 seconds to 2 minutes) into single strands for replication by the 
thermostable DNA polymerase (Jalali et al., 2017). In the next cycle the temperature is reduced to 
roughly 40-60˚C, allowing the oligonucleotide primers to anneal with the denatured DNA target 
and serve as primers for the enzyme DNA polymerase this step takes approximately 15-60 seconds. 
Lastly new DNA is synthesised as the reaction temperature is increased to the ideal temperature 
suited for the DNA polymerase. Most thermostable DNA polymerases temperatures range from 
70-74˚C (Jalali et al., 2017). The extension step allows for the synthesis of new DNA strands by 
the DNA polymerase that extend the annealed primers. The modification of basic PCR lead to the 
expansion of its application. The development of quantitative PCR enabled the quantification of 
target sequences in real time (Jalali et al., 2017). 
 
 
Figure 3.13 : Cycles of conventional PCR within the thermocycler instrument adapted from (Lui et al., 
2009)  
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3.14.1.2 qPCR 
Quantitative polymerase reaction (qPCR) also referred to as real time PCR, is a technique that 
measures and detects PCR products. The process of qPCR occurs in two steps, firstly mRNA is 
isolated and then reverse transcribed to single stranded complementary DNA (cDNA) (Navarro et 
al., 2015). Additional characterization of qPCR is based on the addition of a fluorescent dye, SYBR 
green that can bind to the minor groove of double stranded DNA (dsDNA) amplicons present, 
resulting in increased fluorescence upon DNA-binding that’s proportional to the amount of PCR 
product produced at the end of each cycle (Jalali et al., 2017, Kralik and Ricchi, 2017, Navarro et 
al., 2015). 
 
3.14.2  Protocol 
 
3.14.2.1 RNA isolation  
Hek293 cells were treated with different AFB1 concentrations (IC25, IC50, IC75) for 24hr, untreated 
cells served as the control. The cells were washed 1x with 0.1 M PBS and 500 µl of Trizol and 500 
µl of 0.1 M PBS was added to each flask and the flasks were incubated at room temperature (RT) 
for 5 minutes. Following incubation, the flasks were scrapped, and the contents were transferred to 
1.5 ml eppendorf tubes and stored at -80ºC.  
 
Thereafter, to thawed samples 100 µl of chloroform was added, mixed vigorously for 15 seconds 
and samples were incubated at RT for 2-3 minutes. The samples were then centrifuged (12000 x g, 
4˚C, 15 minutes). While working on ice, the upper aqueous phase was transferred to new 1.5 ml 
eppendorf tube and 250 µl of isopropanol was added to each tube, then the samples were stored 
overnight (-80˚C) overnight. Thawed samples were centrifuged (12000 x g, 4˚C, 20 minutes) and 
the supernatant was removed leaving only the pellet containing total RNA. The pellet was then 
washed with 500 µl of 75% cold ethanol and flicked to loosen the pellet. The tubes were then 
centrifuged again (7400 xg, 4˚C,15 minutes) and thereafter all ethanol was discarded, and the 
samples were air dried for 1-1.5hrs. 
 
Thereafter the pellets were resuspended in 15 µl of nuclease free water (NFH2O) and samples were 
incubated at RT for 2-3 minutes on ice and isolated RNA was quantified using a nanodrop 2000 
(Thermo Fisher Scientific, Johannesburg, S.A.).The purity of RNA was determined using an 
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absorbance ratio of 260/280 nm, samples between 1.8-2 were considered as pure. RNA samples 
were standardized to 5000 ng/µl with nuclease free water (NFH2O) and stored at -80˚C. 
 
3.14.2.2 cDNA synthesis 
Following the manufacturer’s guidelines, RNA was reverse transcribed to cDNA using the 
iScriptTM CDNA synthesis kit. A 20 µl reaction mixture (4 µl of 5x iScript reaction mix, 1 µl iScript 
reverse transcriptase, 11 µl NFH2O and 4 µl RNA sample) was prepared for each sample. The 
prepared samples were placed in a thermocycler and reverse transcribed as follows: 25 °C for 5 
minutes, 42 °C for 30 minutes, 85°C for 5 minutes and final hold at 4°C. The cDNA was diluted 
with 80 µl of NFH20 to obtain a final volume of 100 µl and stored at -80 °C for further use. 
 
3.14.2.3 qPCR 
Working stock solutions of forward and reverse primers were prepared separately according to 
manufacture guidelines (6.25 µl SYBR green, 0.5 µl forward primer, 0.5 µl reverse primer, 3.75 µl 
of NFH20 and 1.5 µl of cDNA) for both the gene of interest and housekeeping gene, this made up 
to a reaction volume of 12.5 µl. The gene of interest was 8-oxoguanine DNA glycosylase (OGG1) 
(Forward primer : 5’-GCATCGTACTCTAGCCTCCAC-3’, Reverse primer : 5’-
AGGACTTTGCTCCCTCCAC-3’,  60°C). The house keeping gene was glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (Forward primer : 5'-TCCCTGAGCTGAACGGGAAG-3', 
Reverse primer :  5'-GGAGGAGTGGGTGTCGCTGT-3'). Each treatment was done in triplicates 
in a plate that was covered with plastic and centrifuged (200 rpm, 37°C, 3 minutes) then placed in 
the CFX Touch™ Real Time PCR Detection System (Bio-Rad; Hercules, California, United 
States).The reaction was subjected to initial denaturation (95°C, 4 minutes), followed by an 
annealing phase (60°C, 40 seconds) which can be altered to accommodate different genes, and 
finally the extension phase (72°C for 30 seconds). To determine the initial amount of DNA present 
in samples a curve was plotted with fluorescent emission over time. The expression of the house 
keeping gene (GAPDH) was also quantified for normalization of the target gene expression. The 
data acquired was analysed using the Livak & Schmittgen (2001) method and presented as relative 
fold change in mRNA expression. 
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3.15  DNA fragmentation  
 
3.15.1  Background  
Deoxyribonucleic acid (DNA) is a negatively charged nucleic acid that when subjected to an 
electric field migrates from negative (anode) to positive (cathode). This assay is based on the 
fragmentation of DNA separated on an agarose gel (Figure 3.14). The visualization of DNA 
migration on the gel is facilitated by the use of intercalating dyes that bind and stain DNA. These 
dyes have been used to indicate DNA quantity, size and quality (Haines et al., 2015). 
 
 
 
Figure 3.14 : The separation of DNA fragments bases on their size and charge on an agarose gel (Prepared 
by author). 
 
3.15.2  Protocol  
Hek293 cells were exposed to various AFB1 concentrations for 24hrs, with untreated cells serving 
as the control. Following treatment, the supernatants were discarded, and cells were rinsed 1x with 
5 ml 0.1 M PBS. Thereafter, 600 µl cell lysis solution (EDTA, Tris-Cl, 0.1% SDS) was added to 
the flasks of treated cells and left at room temperature (RT) for 5 minutes. The flasks were then 
scraped, and the constituents were transferred to 1.5 ml eppendorf tubes then stored at -80˚C 
overnight. To thawed samples, 600 µl potassium acetate was added and the samples were vortexed, 
then invert mixed for 8 minutes. The samples were vortexed once more and centrifuged (13000 
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rpm for 5 min) and the clear supernatant was decanted into eppendorf tubes. To the tubes with the 
supernatants, 600 µl of isopropanol was added and the tubes were invert mixed for 5 minutes then 
centrifuged (13000 rpm for 5 min). After centrifugation the supernatant was decanted to a new 1.5 
ml eppendorf, leaving behind the pellet and isopropanol was added to the tubes (60 µl supernatant, 
200 µl pellet) accordingly. The tubes were invert mixed for 5 minutes and centrifuged (13000 rpm 
for 5 min). The pellet was noted in each tube, pellets were combined for each treatment and 300 µl 
of ethanol was added to the final pellet then vigorously vortexed followed by centrifugation (13000 
rpm for 5 minutes).The ethanol was removed carefully noting the clean white pellet and the tubes 
were dried on an absorbent towel for 1hr. Furthermore, 40 µl of DNA hydration solution (1x TE 
solution) was added to the pellet. Then the samples were vortexed and placed in a water bath (65˚C) 
for 15 minutes. The samples were allowed to cool for 15 minutes and stored at -80˚C. The 
concentration of DNA for each sample was measured using Nanodrop (Nanodrop 2000) and the 
obtained concentrations were standardized to the lowest concentration (100 ng/µl). 
 
3.15.2.1 Agarose gel  
A 2% agarose gel (2 g agarose powder in 100 ml 1x TBE buffer) was prepared. The standardized 
DNA samples were prepared with loading dye (10 µl : 10 µl) then loaded in to gels, a DNA ladder 
of 1kilo base pairs (kb)  was used as a marker for the migration of  DNA samples in the gel and the 
gels were electrophoresed (120 V) monitoring the migration of the samples. The gels were then 
viewed using Molecular Imager® ChemidocTM XRS and Bio-Rad imaging system. 
 
3.16 STATISTICAL ANALYSIS 
GraphPad Prism V5 software was used for the analysis of results. Data was presented as mean ± 
standard deviation (SD). The significant differences among groups were determined using One-
way analysis of variance (ANOVA) and Tukey’s multiple comparisons post-test. The unpaired 
student t-tests with Welch’s correction was also used to measure the significant difference between 
two sample means. A value of p < 0.05 was accepted as an indication of statistical significance. 
All the data represented was obtained from at least three replicates of each experiment, and 
experiments were repeated to confirm the results. 
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CHAPTER 4 : RESULTS  
 
4.1 CELL VIABILITY  
 
4.1.1 MTT assay 
The toxicity of AFB1 in Hek293 cells was assessed using the MTT assay. The results show that at 
lower AFB1 concentrations (log 0.097 - 0.699) a slight increase in Hek293 cell viability was 
observed relative to the control (Figure 4.1). However, a dose dependent decrease was observed at 
higher AFB1 concentrations (log 1.0 - 2.0). Analysis of the curve disclosed that 32.60 µM of AFB1 
inhibited cell proliferation by inducing 50% toxicity in Hek293 cells (IC50).  
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Figure 4.1 : Viability of Hek293 cells after 24 hr treatment with different AFB1 concentrations. A dose 
dependent decline in cell viability was observed at high AFB1 concentrations.  
 
 4.1.2  ATP assay 
The intracellular levels of ATP were evaluated using the Cell Titre Glo TM assay. AFB1 induced a 
decrease in ATP levels in Hek293 cells in a dose dependent manner (Figure 4.2, p < 0.0001 using 
ANOVA, Tukey’s post-test). Significant decreases in ATP concentration were noted at the IC50 (p 
= 0.004) and IC75 (p = 0.0143) relative to the control (Figure 4.2). 
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Figure 4.2 : The ATP concentration decreased in Hek293 cells after 24hr treatment with different 
concentrations of AFB1 (**p = 0.0044 and *p = 0.0143, unpaired student t-test with Welch’s 
correction). 
 
4.2  OXIDATIVE STRESS 
 
4.2.1  TBARS assay 
The TBARS assay was used to quantify MDA levels, a marker of lipid peroxidation in Hek293 
cells treated with different AFB1 concentrations. The dose dependent decline in MDA levels was 
observed AFB1 treated cells (Figure 4.3, p < 0.0001 using ANOVA, Tukey’s post-test). The MDA 
levels dropped from 2.994±0.03402 µM in the control to 0.6432±0.006586 µM at the IC25 (p < 
0.0001). In addition, the higher concentrations of AFB1 induced a decrease from reported control 
MDA levels to 0.4829±0.006044 µM at IC50 (p < 0.0001), and 0.4509±0.007995 µM at IC75 (p < 
0.0001) respectively (Figure 4.3). 
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Figure 4.3 : 24hr treatment with AFB1 induced in a dose dependent decrease in MDA concentration in 
Hek293 cells (*** p < 0.0001 for all treatments, unpaired student t-test with Welch’s correction). 
 
4.2.2  NOS assay 
The concentration of RNS in AFB1-treated Hek293 cells was evaluated using the nitrates assay. 
An increase in nitrates concentration was observed in the IC25 and IC50 treated cells; an increase 
was also observed at the IC75 relative to the control, but was lower than the IC50 (Figure 4.4, p = 
0.0046 using ANOVA, Tukey’s post-test). When compared to the control (2.000±0.3608 µM), a 
non-significant increase to 2.625 ±0.7217 µM and 3.563±0.5413 µM was observed at IC25 and IC75 
respectively, while a significant increase to 6.688±0.9021 µM was observed at IC50 (p = 0.0404, 
Figure 4.4). 
 
C IC25 IC50 IC75
0
2
4
6
8 *
AFB1 treatments (M)
R
N
S 
C
on
ce
nt
ra
ti
on
 (

M
)
 
Figure 4.4 : Treatment with AFB1 induced an increase in the production of reactive nitrogen species in 
Hek293 cells (*p = 0.0444, unpaired student t-test with Welch’s correction).  
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4.2.3  GSH assay 
The GSH assay was used for the quantification of GSH in treated Hek293 cells. The data revealed 
a concentration dependent increase in GSH levels at all AFB1 concentrations (Figure 4.5, p = 
0.0039 using ANOVA, Tukey’s post-test). The GSH levels increased from 23200±486.6 RLU in 
the control to 68160±23650 RLU at IC25 (p = 0.1977), with significant increases to 102300±862.3 
RLU at IC50 (p < 0.0001) and 105000 ±716.8 RLU at IC75 (p < 0.0001).  
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Figure 4.5 : Exposure to AFB1 induced a dose dependent increase in GSH levels in Hek293 cells (***p < 
0.0001, unpaired student t-test with Welch’s correction). 
 
4.2.4  Hsp70 
The expression of proteins in AFB1 treated Hek293 cells was determined using western blotting 
relative to the control. The expression of Hsp70 was upregulated in treated Hek293 cells compared 
to the control (Figure 4.6, p < 0.0001 using ANOVA, Tukey’s post-test). The control expression 
was recorded as 0.8897±0.003612 RBI. An increase to 1.075±0.004250 RBI, 0.9927±0.002614 
RBI, 0.9332±0.003711 RBI was observed at IC25 (p < 0.0001), IC50 (p < 0.0001) and at IC75 (p = 
0.0005) concentrations respectively, relative to the control.  
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Figure 4.6 : Upregulated expression of stress protein Hsp70 after 24hr treatment with AFB1 in Hek293 cells 
(***p < 0.0001, IC25 and IC50; *** p = 0.0005, IC75; unpaired student t-test with Welch’s correction). 
 
4.2.5  Antioxidant response 
The expression of proteins related to the antioxidant response in AFB1 treated Hek293 cells was 
established using western blotting (Figure 4.7). Nrf-2 was significantly upregulated in AFB1 treated 
Hek293 cells, an increase from the control expression of 0.09956±0.001364 RBI to 
0.1740±0.003141 RBI was observed at the IC25 concentration (p < 0.0001). A further increase to 
0.3511±0.003066 RBI was observed at IC50 concentration (p < 0.0001). In addition, an increase to 
0.2060±0.001476 RBI at IC75 concentration was noted (p < 0.0001). SOD2 expression was 
increased from 1.069±0.008645 RBI in the control to 1.277±0.007789 RBI at the IC25 
concentration of AFB1 (p < 0.0001), a further increase to 1.195±0.003530 RBI and 1.486±0.007021 
RBI for the IC50 (p = 0.0009) and IC75 (p < 0.0001) concentrations respectively. GPx was 
upregulated at the IC25 and IC50 concentration of AFB1 to 1.070±0.02179 RBI (p = 0.1459) and 
1.055±0.01705 RBI (p = 0.1846) respectively compared to the control expression of 
1.024±0.008110 RBI; a significant increase to 1.143±0.006078 RBI relative to the control was 
noted at the IC75 (p < 0.0001). Catalase was significantly increased in AFB1-treated Hek293 cells 
relative to the control. Upregulation from control expression (1.788±0.02214 RBI) to 
2.501±0.01745 RBI at IC25 (p < 0.0001), 1.990±0.003122 RBI was at IC50 concentration (p = 
0.0029) and 3.360±0.01842 RBI at the IC75 (p < 0.0001) AFB1 concentration comparative to the 
control. 
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Figure 4.7 : The expression of antioxidant proteins Nrf-2 (***p < 0.0001), SOD2 (***p < 0.0001, IC25 and  IC75; ***p = 0.0009, IC50), GPx (***p < 
0.0001) and catalase (**p < 0.0001, IC25 and  IC75; ***p = 0.0029, IC50) after 24hrs treatment with AFB1 in Hek293 cells, unpaired student t-test with 
Welch’s correction.
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4.3  DNA DAMAGE  
 
4.3.1  SCGE assay  
The SCGE assay was performed to detect DNA fragmentation induced by DNA damage in treated 
Hek293 cells and the untreated cells served as the control. Large intact comet heads indicated no 
DNA fragmentation and the presence of comet tails lengths is an indication of DNA fragmentation. 
A significant dose-dependent increase in comet tail length was observed relative to the control 
(Figure 4.8, p < 0.0001 using ANOVA, Tukey’s post-test). A significant increase from 
6.244±0.1459 µm in the control to 7.046±0.1208 µm, 8.620±0.1370 µm, 9.109±0.1152 µm was 
observed for IC25 (p < 0.0001), IC50 (p < 0.0001) and IC75 (p < 0.0001) concentrations of AFB1 
respectively in treated Hek293 cells. 
 
 
Figure 4.8 : Comet tails of Hek293 cells after 24hr treatment with AFB1. A significant increase in comet 
tail length was observed in the treated cells relative to the control (***p < 0.0001, unpaired student t-test 
with Welch’s correction). 
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4.3.2 DNA fragmentation 
To further validate the damage to DNA in AFB1 treated Hek293 cells, DNA fragmentation was 
assessed by running isolated DNA samples of the treated cells on an agarose gel; untreated cells 
served as the control. The genomic DNA of AFB1 treated Hek293 cells showed fragmentation in 
treated cells except the control which indicated that AFB1 exposure induced DNA double strand 
breaks in Hek293 cells. 
 
 
 
Figure 4.9 : Fragmentation of DNA induced by 24hr exposure to AFB1 in Hek293 cells.   
 
4.3.3  OGG1 expression 
The expression of mRNA in Hek293 cells after 24hr exposure to AFB1 was quantified using qPCR. 
A non-significant concentration dependent increase in OGG1 mRNA expression was observed at 
IC25 (p = 0.3837) and IC50 (p = 0.7867) concentrations in AFB1 treated Hek293 cells, and an 
increase at   IC75 (p = 0.2145) was observed compared to the control. 
56 
 
  
 
Figure 4.10 : Increased mRNA levels of OGG1 after 24 hr treatment with AFB1 in Hek293 cells. 
 
4.4  CELL DEATH  
 
4.4.1  Caspase activity  
Intracellular activities of caspases 8, 9 and 3/7 were measured using luminometry. Treatment of 
cells with AFB1 decreased caspase 8 activity (Figure 4.11A) activity in Hek293 cells. There was a 
decrease to 4329000±724.6 RLU, 2025000±956800 RLU, 3289000±9904 RLU was noted at IC25 
(p = 0.6847), IC50 (p = 0.1336) and IC75 (p = 0.0624) AFB1 concentrations sequentially from control 
activity of 4421000±196700 RLU. Compared to the control (3216000±586800 RLU), only slight 
but non-significant increases in the activity of caspase 9 were observed (Figure 4.11B). Caspase 9 
activity increased to 3337000±401700 RLU at IC25 (p = 0.8928), 3806000±49500 RLU at IC50 (p 
= 0.5082) and 3432000±90480 at IC75 (p = 0.7773). The increase in caspase 3 activity compared 
to the control (455900±13440 RLU) was not significant (Figure 4.11C). An increase at IC25 (p = 
0.1252) to 617500± 61860 RLU and 541300±46180 RLU IC50 (p = 0.2177) were noted, while 
caspase 3 activity was similar to the control for the IC75 (p = 0.775) with 450700±9904 RLU in 
AFB1 treated Hek293 cells. 
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Figure 4.11 : The activity of initiator and executioner caspases in AFB1 treated Hek293 cells, A) caspase 8, 
B) caspase 9 and C) caspase 3/7. 
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4.4.2  Apoptosis-related proteins 
Evaluation of the expression apoptosis-related protein in AFB1 treated Hek293 cells was 
ascertained using western blotting. Upregulation in the expressions of p53, Bax and c-Parp was 
observed in treated Hek293 cells comparative to the control (Figure 4.14). Control expression for 
p53 was recorded as 1.214±0.01316 RBI and were elevated to 2.046±0.02566 RBI at IC25 (p < 
0.0001). In addition, an increase to 1.506±0.01500 RBI and 1.553±0.01318 RBI was observed at 
IC50 (p < 0.0001) and IC75 (p < 0.0001) concentrations respectively (Figure 4.12A). Regarding the 
expression of pro-apoptotic Bax protein, a significant concentration dependent increase was 
observed in AFB1 treated Hek293 cells (Figure 4.12B). An increase from control expression of 
0.5447±0.01588 RBI to 0.7113±0.01268 RBI was observed at IC25 (p = 0.0004) concentration with 
a noted significant increase to 0.8567±0.003298 RBI at IC50 (p = 0.0010) relative to the control, 
and an observed increase to 1.005±0.01354 RBI was noted at the IC75 (p < 0.0001) concentration. 
The expression of c-Parp (Figure 4.12C) showed an increase from 0.8430±0.003773 RBI in the 
control to 1.521±0.004865 RBI at IC25 (p < 0.0001), while an increase to 1.111±0.008022 RBI and 
1.225±0.01154 RBI was noted at IC50 (p < 0.0001) and IC75 (p < 0.0001). 
 
The expression of c-IAP was significantly increased in treated cells relative to the control (Figure 
4.13A), an increase from 0.7220±0.005607 RBI in the control to 1.300±0.02637 RBI was noted at 
IC25 concentration (p = 0.0002). An increase from recorded control levels to 0.8199±0.01008 RBI 
and 0.9026± 0.1016 RBI was observed at the IC50 concentration (p = 0.0011) and IC75 concentration 
(p < 0.0001). A dose dependent increase in the expression of NF-κb (Figure 4.13B) was observed 
in AFB1 treated Hek293 cells, the control expression of NF-κb was recorded as 1.272±0.009986 
RBI, an increase from recorded control expression to 2.413±0.01762 RBI, 2.538±0.02202 RBI and 
2.544±0.01727 RBI was noted at the IC25 concentration (p < 0.0001), IC50 concentration (p < 
0.0001), and IC75 concentration (p < 0.0001) respectively. 
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Figure 4.12 : The protein expression of p53 (***p < 0.0001), Bax (***p = 0.0004, IC25; **p = 
0.0010, IC50; ***p < 0.0001, IC75) and c-Parp IC25 (***p < 0.0001) were increased in AFB1 treated 
Hek293 cells (unpaired student t-test with Welch’s correction).   
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Figure 4.13 : Upregulated expression of c-IAP (***p = 0.0002, IC25; **p = 0.0011, IC50; ***p < 0.0001, 
IC75) and NF-κb (***p < 0.0001) in AFB1 treated Hek 293 cells (unpaired student t-test with Welch’s 
correction). 
 
4.4.3  Mode of cell death 
The annexin V assay was used to detect apoptotic cells by measuring the exposure of 
phosphatidylserine (PS) on the outer leaflet of the cell membrane during apoptotic processes. Since 
annexin binds to PS, the findings indicate that AFB1 decreased externalization of PS. Thus, annexin 
binding in treated cells was less compared to the control. Control apoptotic cells were recorded as 
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886100±21410 RLU (Figure 4.14). A decrease to 695300 ± 40650 RLU was observed at the IC25 
(p = 0.0254) concentration and to 736800±39000 RLU at the IC50 (p = 0.0439) concentration 
relative to the control (Figure 4.14); phosphatidylserine externalisation at the IC75 was similar to 
the control (p = 0.9755). 
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Figure 4.14 : AFB1 induced a decrease in early apoptotic cells in treated Hek293 cells (*p = 0.0254, IC25; 
*p = 0.0439, IC50; unpaired student t-test with Welch’s correction). 
 
Necrotic cells were quantified to determine the mode of cell death induced by AFB1 in treated 
Hek293 cells. The presence of necrotic cells was detected using the necrosis assay which measured 
the permeability of the plasma membrane to an impermeable fluorescent dye. Control necrotic cells 
were recorded as 886100±37080 RFU (Figure 4.15), a decrease to 695300±70410 RFU was 
observed at the IC25 (p = 0.2516) concentration. A further decrease relative to the control to 
736800±67550 RFU and 882800±159700 RFU was noted at IC50 (p = 0.3033) and IC75 (p = 0.9873) 
concentrations respectively. 
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Figure 4.15 : 24hr treatment with AFB1 decreased levels of necrotic cells in treated Hek293 cells. 
 
 Upon membrane damage cells release the enzyme lactate dehydrogenase (LDH) into the 
extracellular space and its release can indicate membrane damage (Kumar et al., 2018). 
Extracellular LDH levels were quantified using the LDH assay. A non-significant decrease in LDH 
concentration occurred for all treatments (Figure 4.12). A decrease from 0.1657±0.02627 OD in 
the control to 0.1110±0.02078 OD, 0.1347±0.02050 OD, 0.1267±0.02858 OD was noted at the 
IC25 (p = 0.2012), IC50 (p = 0.4028) and IC75 (p = 0.3891) concentrations respectively (Figure 4.12). 
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Figure 4.16 : Extracellular LDH levels decreased after 24hr treatment with AFB1 in Hek293 cells. 
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CHAPTER 5 : DISCUSSION 
 
This chapter describes in detail what the obtained results of this study indicate and further outlines 
the mechanism by which AFB1 exerts its effects in Hek293 cells. Furthermore, the study limitations 
and recommendations are also included in this chapter. 
 
Mycotoxins are a group of toxic secondary metabolites produced by fungi that colonise dietary 
staples.  They present a growing health concern associated with mortality and morbidity in animals 
and humans. AFB1 is of great concern worldwide because it is considered the most potent 
mycotoxin and is classified as a group 1 carcinogen (da Rocha et al., 2014, Alshannaq and Yu, 
2017, Zinedine and El Akhdari, 2019). Exposure to AFB1 is mainly through the diet, as AFB1 is 
frequently found as a contaminant in maize, peanuts and wheat which are major staple foods 
especially in South Africa (Alshannaq and Yu, 2017). Carcinogenic, immunotoxic, teratogenic and 
mutagenic effects have been reported in both humans and animals.  Exposure is linked to several 
diseases including liver cancer in humans (Moosa, 2019) and nephrotoxicity in rats (Abdel-Hamid 
and Firgany, 2015, Asa et al., 2018, Yilmaz et al., 2018). However, AFB1 effects on the human 
kidney have not been fully elucidated. This study therefore investigated the cytotoxic effects of 
AFB1 exposure on Hek293 cells. 
 
All living organisms require energy to survive; the energy is provided by the hydrolysis of ATP 
and is used for various cellular activities (Yong et al., 2019). Mitochondria are the metabolic hub 
of cells that perform the essential function of oxidative phosphorylation, resulting in the production 
of ATP necessary for cell viability and survival (Yong et al., 2019). The present study exposed 
Hek293 cells to different AFB1 concentrations and cell viability was evaluated using the MTT 
assay. This study showed that viable Hek293 cells reduced the MTT salt to formazan and decreased 
cell viability (Figure 4.1). The result corroborates several studies that have demonstrated that AFB1 
decreases viability in human brain microvascular endothelial cells, hematopoietic stem cells, 
human brain macrovascular endothelial cells, human hepatocellular carcinoma cells and human 
epithelial colorectal adenocarcinoma cells (Qureshi et al., 2015, Yip et al., 2017, Al-Ouqaili, 2018, 
Huang et al., 2018, Meneely et al., 2018). The suggested decrease in mitochondrial succinate 
dehydrogenase activity or NADH (Stockert et al., 2018), both essential components of the electron 
transfer, would negatively impact oxidative phosphorylation; ATP will be depleted and cell 
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viability is lost resulting in cell death (Yong et al., 2019). The decrease in Hek293 cell viability 
corresponded with a dose-dependent decrease in ATP levels (Figure 4.2), and correlated with 
decreased ATP levels reported following AFB1 administration to HepG2 cells (Liu et al., 2014).  
 
An attempt by the Hek293 cells to enhance the metabolic rate to replenish the depleted ATP could 
lead to oxidative stress, which is associated with an increased production of ROS (Forrester et al., 
2018). Several studies have demonstrated a role for AFB1 in the onset of oxidative stress; AFB1 
forms ROS in rat liver, duck liver, mouse lung, chicken liver and the kidney of rats (Shen et al., 
1994, Shen et al., 1996, El-Nekeety et al., 2011, Abdel-Hamid and Firgany, 2015). Although  
mitochondria are a major source of ROS produced as by-products of cellular respiration in the 
ETC, they are also highly susceptible to ROS molecules and their harmful effects (Milkovic et al., 
2019). Specifically, mitochondria produce O2
– from O2 (Tong et al., 2015, Di Meo et al., 2016, 
Milkovic et al., 2019). The O2
– is converted to H2O2 in a dismutation reaction catalysed by SOD 
or it can react with  NO to form peroxynitrite (ONOO–) (Di Meo et al., 2016). In this study, the 
increased SOD2 (Figure 4.7) and RNS (Figure 4.4) provide evidence of increased O2
–. 
Furthermore, the noted increase in SOD2 expression at all AFB1 exposures (Figure 4.7) can be 
attributed to the correspondingly increased expression of NF-κb (Figure 4.13A), as SOD2 is one 
of the antioxidant targets of NF-κb (Morgan and Liu, 2011). 
 
H2O2 produced in the dismutation reaction has several fates. It may be converted to the potent OH
-
using the Fenton reaction (Di Meo et al., 2016). Both O2
– and OH- are able to oxidise cellular 
macromolecules including proteins and lipids (Di Meo et al., 2016, Milkovic et al., 2019). 
Decreased MDA levels at all doses of AFB1 (Figure 4.3) is characteristic of decreased lipid 
peroxidation and implies that membranes were spared from the cytotoxic effects of free radicals 
(Figure 4.3); the decreased membrane damage is supported by decreased LDH release from all 
AFB1-treated Hek293 cells (Figure 4.16). This protection could be conferred by the upregulation 
of another pathway for H2O2, where H2O2 is reduced to water using GSH (Tong et al., 2015). 
Alternatively, catalase converts H2O2 to water and O2 (Tong et al., 2015, Di Meo et al., 2016). 
These antioxidants protect cells from the deleterious effects of H2O2 (Dhawan, 2014). Protein 
expression of both GPx (Figure 4.7) and catalase (Figure 4.7) was increased for all AFB1 
treatments, but particularly for the IC75 AFB1 treatment. The functioning of GPx is dependent on 
adequate reduced glutathione (GSH); increased GSH in all AFB1-treated cells (Figure 4.5) was 
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employed in the reduction of lipid hydroperoxides and thus correlates with the observed decline in 
MDA levels at all doses of AFB1 (Figure 4.3). Overall, decreased MDA (Figure 4.3) in this study 
suggests that the antioxidant response in human kidney cells sufficiently keeps ROS within levels 
suitable to maintain cellular homeostasis. Thus, the Hek293 cells are able to resist oxidative stress; 
this adaptive advantage is known to permit cancer cells to increase their metabolic rate, proliferate 
and to escape free radical damage (Sainz et al., 2012) and may indicate a progression to cancer. 
 
The antioxidant response is modulated by the upregulation of Nrf-2 (Figure 4.7) in all treated 
Hek293 cells. Nrf-2 is a transcription factor involved in the activation of antioxidants and 
cytoprotective enzymes that protect cells from excess oxidative stress by binding to antioxidant 
response elements (AREs) (Kavian et al., 2018). Despite an overwhelming antioxidant response, 
the upregulated expression of the stress response protein, Hsp70 (Figure 4.6) at all AFB1 doses 
demonstrates that AFB1 induced oxidative stress in Hek293 cells. Several studies also show the 
involvement of AFB1 in the induction of oxidative stress in rat kidney, splenic lymphocytes of 
broilers, and heart tissues of rats (Abdel-Hamid and Firgany, 2015, Chen et al., 2016, Yilmaz et 
al., 2018). 
 
Oxidative damage to DNA is also possible during episodes of oxidative stress. It may manifest as 
lesions on DNA, breaks in DNA strands or faulty links and base gaps in sequences (Wang et al., 
2018). Cells respond to oxidative DNA damage using the base excision repair (BER) pathway that 
employs enzymes such as OGG1, a DNA glycosylase involved in BER (Wang et al., 2018, 
Vlahopoulos et al., 2019). OGG1 is a marker of oxidative DNA damage (Wang et al., 2018). The 
increase in OGG1 (Figure 4.10) may reflect increased strand breaks in DNA that require repair. 
Strand breaks in this study are indicated by DNA laddering (Figure 4.7) and increased comet tail 
lengths (Figure 4.8) both of which indicate oxidative damage to DNA. Since OGG1 is 
transcriptionally regulated by p53, as well as the observed increase in DNA damage, the 
upregulation of p53 (Figure 4.12) was not surprising. Failure to repair DNA results in activation of 
the cell death program by p53. 
 
Cell death is mediated by multiple pathways, including apoptosis and necrosis (Jog and Caricchio, 
2014). Intact and ruptured plasma membranes are considered as hallmarks of apoptosis and necrotic 
cell death respectively (Zhang et al., 2018). The results of this study revealed a decrease in necrosis 
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(Figure 4.15). Evidence for the decreased necrosis is provided by the corresponding decrease in 
LDH (Figure 4.16) released from treated Hek293 cells at all concentrations of AFB1; this effect 
was not dependent on dose. It is further supported by decreased MDA levels and lipid peroxidation 
(Figure 4.3) indicating reduced membrane damage. Thus, homeostasis is maintained, the influx of 
water and extracellular ions leading to cell swelling and rupture is prevented, and necrotic cell 
death is avoided (Zhang et al., 2018). This indicates that treatment of cells with AFB1 induced a 
decrease in necrotic cell death at all AFB1 concentrations relative to the normal untreated cells.  
 
Essential for the occurrence of apoptosis is a group of cysteine proteases (caspases) which become 
activated in response to pro-apoptotic signals (McIlwain et al., 2013). In the present study, AFB1 
exposure lead to a decrease in caspase 8 activity (Figure 4.11A) in Hek293 cells indicating that the 
extrinsic pathway of apoptosis was not activated. The intrinsic pathway of apoptosis is controlled 
by the Bcl-2 family. Bax is a pro-apoptotic member of the Bcl-2 family (Aubrey et al., 2018). The 
increase in Bax (Figure 4.12B), may have been triggered by upregulation of p53 (Figure 4.12A). 
The tumour suppressor protein p53, aids in DNA repair and can also initiate cell death, DNA 
damage was increased as described earlier. p53 activation results in transcription of pro-apoptotic 
PUMA and NOXA that bind to anti-apoptotic Bcl-2, freeing Bax to dimerize into the mitochondrial 
membrane forming pores that increase permeabilization of the mitochondrial outer membrane 
(Peng et al., 2016, Aubrey et al., 2018). This facilitates the release of cytochrome c, apoptosis 
inducing factor (AIF), endonuclease G, and Smac/DIABLO from the mitochondria (Peng et al., 
2016). Subsequently, cytochrome c binds to Apaf-1 forming an apoptosome and facilitating the 
autocatalytic activation of procaspase 9. Activated caspase 9 (Figure 4.11B) cleaves and activates 
the executioner caspase 3 (Figure 4.11C) leading to the cleavage of Parp. The cleavage of Parp 
(Figure 4.12C) renders the enzyme inactive which further explains the observed DNA 
fragmentation (Figure 4.9) and the progression to apoptosis (Peng et al., 2016). Thus, the 
mitochondrial pathway of apoptosis was triggered in Hek293 cells after exposure to AFB1. 
 
Despite the upregulation of p53 (Figure 4.12A) and activation of caspases via the intrinsic pathway 
(Figure 4.11B), PS was not externalised (Figure 4.14) at all concentrations of AFB1. Thus, a key 
hallmark of apoptosis did not occur; this translates to decreased cell death and suggests that the 
inhibition of the intrinsic pathway apoptosis might be a mechanism by which AFB1 could cause 
cancer in kidney cells. Indeed, inhibition of cell death is a hallmark of cancer (Aubrey et al., 2018). 
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Progression of the intrinsic pathway of apoptosis may also have been hindered by the expression 
of c-IAP (Figure 4.13A) that was upregulated in this study. Inhibitors of apoptosis (IAPs) have 
been reported to regulate cell death through caspase inhibition; however, despite their ability to 
bind to caspases, recent work has reported that cellular IAPs (c-IAPs) do not possess the ability to 
inhibit caspase activation (Kocab and Duckett, 2016). 
 
It has been demonstrated that AFB1 induces apoptosis in splenic lymphocytes, cardiomyocytes of 
rats, human bronchial epithelial (B-2A13) cells and human hepatocytes (Liu et al., 2014, Chen et 
al., 2016, Ge et al., 2017). The induction of apoptosis in broiler hepatocytes as reported by Liu and 
Wang (2016) revealed that increased caspase 9 and caspase 3 activities and increased Bax 
expression lead to the activation of the intrinsic apoptotic pathway (Liu and Wang, 2016). In 
addition, Yang (2012) demonstrated that AFB1 increased the activity of caspase 3, increased the 
expression of apoptotic Bax and c-Parp in B-2A13 cells (Yang et al., 2012). Moreover, Liu et al. 
(2014) also discovered that AFB1 induced an increase in the expression of apoptotic proteins p53 
and Bax hence activation of caspase 3 in human hepatocytes (Liu et al., 2014). The results of this 
study correlated with the previous finding as the expression of p53 (Figure 4.12A), Bax (Figure 
4.12 B), caspase 9 (Figure 4.11A) and caspase 3 activity (Figure 4.11C), and c-Parp expression 
was increased resulting in  activating the intrinsic pathway of apoptosis.  
 
Even though c-IAPs are poor inhibitors of caspase activity, they have been linked to the regulation 
of the NF-κb signalling pathway, which can contribute to determination of cell fate (Kocab and 
Duckett, 2016). The results of this study revealed that AFB1 increased the expression of NF-κb 
(Figure 4.13B) in treated Hek293 cells; NF-κb is an apoptosis regulator that activates survival 
genes. This may predispose kidney cells to the potential cancer-causing effects of AFB1. It has 
been previously reported that AFB1 increases NF-κb  protein expression in broiler chicks, which 
correlates with the observed increased expression in Hek293 cells (Rajput et al., 2019). 
 
The results of this study suggested that AFB1 induced a decrease in cell viability through the 
induction of oxidative stress which lead to cell death through the activation of the intrinsic pathway 
of apoptosis. Furthermore, no relationship was established between dosage and AFB1 cytotoxicity 
in Hek293 cells. However, future studies may use concentrations greater than 100 µM and also 
evaluate the effects of chronic AFB1 exposure as individuals are exposed to AFB1 on a day to day 
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basis. However, methods of eradicating or minimizing the toxic effects of AFB1 are essential to 
maintain human health. The Hek293 cell line was an appropriate model to use for evaluating the 
effects of AFB1 on kidney cells as its exhibits the expression of membrane proteins and optimal 
biological activity of target proteins.  
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CHAPTER 6 : CONCLUSION 
 
The results of this study are summarised in Figure 6.1. The present study demonstrated that 
exposure to high AFB1 concentrations inhibited Hek293 cell viability evidenced by the noted 
decrease in ATP concentrations in treated cells. An overwhelming antioxidant response was 
demonstrated in AFB1-treated Hek293 cells by the upregulation of Nrf-2, SOD2, GPx, Catalase 
and increased GSH levels which correlated with decreased lipid peroxidation and membrane 
damage in treated cells. Despite the perceived overwhelming antioxidant response, RNS 
production increased in AFB1-treated Hek293 cells, subjecting cells to high levels of free radicals 
and resulting in oxidative stress, which was confirmed by the increased expression of Hsp70. In 
response to free radical production oxidative DNA damage was noted in treated Hek293 cells by 
increased mRNA levels of OGG1, increased comet tail lengths and fragmented DNA. Furthermore, 
the observed upregulated p53 in response to DNA damage failed to initiate DNA repair 
mechanisms, therefore apoptotic cell death mechanisms were activated. The upregulated Bax lead 
to activation of caspase 9 and 3/7, and subsequent execution of the intrinsic pathway of apoptosis. 
However, the increase in c-IAP expression hindered the extrinsic pathway of apoptosis by 
inhibiting caspase 8 activation in treated cells. Confirmation that AFB1 induced apoptotic cell death 
in Hek293 cells was noted as necrotic cells decreased in treated cells. Survival mechanisms of 
escaping cell death induced by AFB1 were observed in treated cells as NF-κb was upregulated and 
a decrease in externalisation of PS which is considered as a hallmark of apoptosis was observed. 
 
Further studies need to ascertain the effects chronic exposure to AFB1 as this study only 
investigated the effects of acute exposure to AFB1 in human cells. Considering that most of AFB1 
susceptible foods are a major part of the South African diet, future studies might investigate 
possibilities of ameliorating the toxic effects of AFB1 in humans using drugs or medicinal plants. 
Lastly, this study showed the need for the application of safety measures for controlling AFB1 
concentration in commercially produced products.  
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Figure 6.1 : Proposed mechanisms by which AFB1exerts its toxic effects on Hek293 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
REFERENCES 
 
ABDEL-HAMID, A. A. & FIRGANY, A. E.-D. L. 2015. Vitamin E supplementation ameliorates 
aflatoxin B1-induced nephrotoxicity in rats. Acta histochemica, 117, 767-779. 
ADAN, A., KIRAZ, Y. & BARAN, Y. 2016. Cell proliferation and cytotoxicity assays. Current 
pharmaceutical biotechnology, 17, 1213-1221. 
AL-HAMMADI, S., MARZOUQI, F., AL-MANSOURI, A., SHAHIN, A., AL-SHAMSI, M., 
MENSAH-BROWN, E. & SOUID, A.-K. 2014. The cytotoxicity of aflatoxin B1 in 
human lymphocytes. Sultan Qaboos University Medical Journal, 14, e65. 
AL-OUQAILI, M. T. S. 2018. Depending on HPLC and PCR, detection of aflatoxin B1 extracted 
from Aspergillus flavus strains and it’s cytotoxic effect on AFB treated-hematopoietic 
stem cells obtained from human umbilical cord. Asian Journal of Pharmaceutics (AJP): 
Free full text articles from Asian J Pharm, 12. 
ALSHANNAQ, A. & YU, J.-H. 2017. Occurrence, toxicity, and analysis of major mycotoxins in 
food. International journal of environmental research and public health, 14, 632. 
ASA, S. A., EL-SHAYMAA, E., MOSELHY, W. A., HASSAN, N. E.-H. Y. & HASSAN, A. A. 
2018. Aflatoxin induced renal toxicity in Albino rats and the ameliorative effect of green 
tea aqueous extract: Histological, Morphometric and Immunohisto-chemical Study. 
Journal of Experimental and Applied Animal Sciences, 2, 273-285. 
AUBREY, B. J., KELLY, G. L., JANIC, A., HEROLD, M. J. & STRASSER, A. 2018. How does 
p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell 
death and differentiation, 25, 104. 
AYALA, A., MUÑOZ, M. F. & ARGÜELLES, S. 2014. Lipid peroxidation: production, 
metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. 
Oxidative medicine and cellular longevity, 2014. 
BASU, S. 2007. The enigma of in vivo oxidative stress assessment: isoprostanes as an emerging 
target. Scandinavian Journal of Food and Nutrition, 51, 48-61. 
BBOSA, G. S., KITYA, D., LUBEGA, A., OGWAL-OKENG, J., ANOKBONGGO, W. W. & 
KYEGOMBE, D. B. 2013a. Review of the biological and health effects of aflatoxins on 
body organs and body systems. Aflatoxins-recent advances and future prospects, 12, 239-
265. 
BBOSA, G. S., KITYA, D., ODDA, J. & OGWAL-OKENG, J. 2013b. Aflatoxins metabolism, 
effects on epigenetic mechanisms and their role in carcinogenesis. Health, 5, 720-726. 
BBOSA, G. S., KITYA, D., ODDA, J. & OGWAL-OKENG, J. 2013c. Aflatoxins metabolism, 
effects on epigenetic mechanisms and their role in carcinogenesis. Health, 5, 14. 
BERNABUCCI, U., COLAVECCHIA, L., DANIELI, P. P., BASIRICÒ, L., LACETERA, N., 
NARDONE, A. & RONCHI, B. 2011. Aflatoxin B1 and fumonisin B1 affect the 
oxidative status of bovine peripheral blood mononuclear cells. Toxicology in vitro, 25, 
684-691. 
CÂMARA, N. O. S., ISEKI, K., KRAMER, H., LIU, Z.-H. & SHARMA, K. 2017. Kidney 
disease and obesity: epidemiology, mechanisms and treatment. Nature Reviews 
Nephrology, 13, 181. 
CARVAJAL-MORENO, M. 2015. Metabolic changes of aflatoxin B1 to become an active 
carcinogen and the control of this toxin. Immunome Research, 11, 1. 
CHEN, J., CHEN, K., YUAN, S., PENG, X., FANG, J., WANG, F., CUI, H., CHEN, Z., YUAN, 
J. & GENG, Y. 2016. Effects of aflatoxin B1 on oxidative stress markers and apoptosis of 
spleens in broilers. Toxicology and industrial health, 32, 278-284. 
72 
 
COULOMBE JR, R. A. 1994. Nonhepatic disposition and effects of aflatoxin B1. The Toxicology 
of Aflatoxins. Elsevier. 
CSONKA, C., PÁLI, T., BENCSIK, P., GÖRBE, A., FERDINANDY, P. & CSONT, T. 2015. 
Measurement of NO in biological samples. British journal of pharmacology, 172, 1620-
1632. 
DA ROCHA, M. E. B., FREIRE, F. D. C. O., MAIA, F. E. F., GUEDES, M. I. F. & RONDINA, 
D. 2014. Mycotoxins and their effects on human and animal health. Food Control, 36, 
159-165. 
DE OLIVEIRA, C. A. & CORASSIN, C. H. 2014. Aflatoxins. Future Medicine. 
DENG, J., LING, Z., NI-YA, Z., KARROW, N. A., CHRISTOPHER, S. K., DE-SHENG, Q. & 
LV-HUI, S. 2018. Aflatoxin B1 metabolism: Regulation by phase I and II metabolizing 
enzymes and chemoprotective agents. Mutation research/reviews in mutation research. 
DHAWAN, V. 2014. Reactive oxygen and nitrogen species: general considerations. Studies on 
Respiratory Disorders. Springer. 
DI MEO, S., REED, T. T., VENDITTI, P. & VICTOR, V. M. 2016. Role of ROS and RNS 
sources in physiological and pathological conditions. Oxidative Medicine and Cellular 
Longevity, 2016. 
EL-NEKEETY, A. A., MOHAMED, S. R., HATHOUT, A. S., HASSAN, N. S., ALY, S. E. & 
ABDEL-WAHHAB, M. A. 2011. Antioxidant properties of Thymus vulgaris oil against 
aflatoxin-induce oxidative stress in male rats. Toxicon, 57, 984-991. 
ELWAHAB, H. A. 2017. The role of the glutathione system in regulating the levels of ROS 
neutralisation in the endothelial cells of the blood-brain barrier. 
ESCOBAR, M. L., ECHEVERRÍA, O. M. & VÁZQUEZ-NIN, G. H. 2015. Necrosis as 
programmed cell death. Intech Open Science, 419-34. 
FERNANDES, T., FERRÃO, J. & BELL, V. 2017. Mycotoxins, food and health. J. Nutr. Health 
Food Sci, 5, 1-10. 
FIUME, L., MANERBA, M., VETTRAINO, M. & DI STEFANO, G. 2014. Inhibition of lactate 
dehydrogenase activity as an approach to cancer therapy. Future medicinal chemistry, 6, 
429-445. 
FORRESTER, S. J., KIKUCHI, D. S., HERNANDES, M. S., XU, Q. & GRIENDLING, K. K. 
2018. Reactive oxygen species in metabolic and inflammatory signaling. Circulation 
research, 122, 877-902. 
GE, J., YU, H., LI, J., LIAN, Z., ZHANG, H., FANG, H. & QIAN, L. 2017. Assessment of 
aflatoxin B1 myocardial toxicity in rats: mitochondrial damage and cellular apoptosis in 
cardiomyocytes induced by aflatoxin B1. Journal of International Medical Research, 45, 
1015-1023. 
GLASSOCK, R. J. & RULE, A. D. 2016. Aging and the kidneys: anatomy, physiology and 
consequences for defining chronic kidney disease. Nephron, 134, 25-29. 
GUENGERICH, F. P. 2015. Human cytochrome P450 enzymes. Cytochrome P450. Springer. 
HAINES, A. M., TOBE, S. S., KOBUS, H. J. & LINACRE, A. 2015. Properties of nucleic acid 
staining dyes used in gel electrophoresis. Electrophoresis, 36, 941-944. 
HEDSTRÖM, M. & MATTIASSON, B. 2015. Screening of self-assembled monolayer for 
aflatoxin B1 detection using immune-capacitive sensor. Biotechnology Reports, 8, 144-
151. 
HUANG, S., ZHENG, N., FAN, C., CHENG, M., WANG, S., JABAR, A., WANG, J. & 
CHENG, J. 2018. Effects of aflatoxin B1 combined with ochratoxin A and/or zearalenone 
on metabolism, immune function, and antioxidant status in lactating dairy goats. Asian-
Australasian journal of animal sciences, 31, 505. 
73 
 
HUSSAIN, Z., KHAN, M. Z. & HASSAN, Z. 2008. Production of aflatoxins from Aspergillus 
flavus and acute aflatoxicosis in young broiler chicks. Pak. J. Agri. Sci, 45, 95-102. 
JALALI, M., ZABOROWSKA, J. & JALALI, M. 2017. The Polymerase Chain Reaction: PCR, 
qPCR, and RT-PCR. Basic Science Methods for Clinical Researchers. Elsevier. 
JEDRZEJCZAK-SILICKA, M. 2017. History of cell culture, InTech. 
JOG, N. R. & CARICCHIO, R. 2014. The role of necrotic cell death in the pathogenesis of 
immune mediated nephropathies. Clinical immunology, 153, 243-253. 
KAVIAN, N., MEHLAL, S., JELJELI, M., SAIDU, N. E. B., NICCO, C., CERLES, O., 
CHOUZENOUX, S., CAUVET, A., CAMUS, C. & AIT DJOUDI, M. 2018. The Nrf2-
antioxidant response element signaling pathway controls fibrosis and autoimmunity in 
scleroderma. Frontiers in immunology, 9, 1896. 
KIRK, G. D., LESI, O. A., MENDY, M., SZYMANSKA, K., WHITTLE, H., GOEDERT, J. J., 
HAINAUT, P. & MONTESANO, R. 2005. 249 ser TP53 mutation in plasma DNA, 
hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene, 24, 5858. 
KNIGHTS, K. M., ROWLAND, A. & MINERS, J. O. 2013. Renal drug metabolism in humans: 
the potential for drug–endobiotic interactions involving cytochrome P450 (CYP) and 
UDP‐glucuronosyltransferase (UGT). British journal of clinical pharmacology, 76, 587-
602. 
KOCAB, A. J. & DUCKETT, C. S. 2016. Inhibitor of apoptosis proteins as intracellular 
signaling intermediates. The FEBS journal, 283, 221-231. 
KRALIK, P. & RICCHI, M. 2017. A basic guide to real time PCR in microbial diagnostics: 
definitions, parameters, and everything. Frontiers in microbiology, 8, 108. 
KUMAR, P., MAHATO, D. K., KAMLE, M., MOHANTA, T. K. & KANG, S. G. 2017. 
Aflatoxins: a global concern for food safety, human health and their management. 
Frontiers in microbiology, 7, 2170. 
KUMAR, P., NAGARAJAN, A. & UCHIL, P. D. 2018. Analysis of cell viability by the lactate 
dehydrogenase assay. Cold Spring Harbor Protocols, 2018, pdb. prot095497. 
KUMAR, V. V. 2018. Aflatoxins: Properties, toxicity and detoxification. Nutrition and Food 
science International Journal, 6, 555696. 
KUTSCHERA, U. & NIKLAS, K. J. 2013. Metabolic scaling theory in plant biology and the 
three oxygen paradoxa of aerobic life. Theory in Biosciences, 132, 277-288. 
LAKSHMANAN, I. & BATRA, S. K. 2013. Protocol for Apoptosis Assay by Flow Cytometry 
Using Annexin V Staining Method. Bio-protocol, 3. 
LAWRENCE, E. A., DOHERTY, D. & DHANDA, R. 2018. Function of the nephron and the 
formation of urine. Anaesthesia & Intensive Care Medicine, 19, 249-253. 
LI, H., XING, L., ZHANG, M., WANG, J. & ZHENG, N. 2018. The toxic effects of aflatoxin B1 
and aflatoxin M1 on kidney through regulating L-proline and downstream apoptosis. 
BioMed research international, 2018. 
LI, W., SANG, Y. & ZHANG, G. 2017. Combined cytotoxicity of aflatoxin B1 and 
deoxynivalenol to hepatoma HepG2/C3A cells. World Mycotoxin Journal, 10, 387-399. 
LING, X. C. & KUO, K.-L. 2018. Oxidative stress in chronic kidney disease. Renal Replacement 
Therapy, 4, 53. 
LIU, Y., DU, M. & ZHANG, G. 2014. Proapoptotic activity of aflatoxin B1 and sterigmatocystin 
in HepG2 cells. Toxicology reports, 1, 1076-1086. 
LIU, Y. & WANG, W. 2016. Aflatoxin B1 impairs mitochondrial functions, activates ROS 
generation, induces apoptosis and involves Nrf2 signal pathway in primary broiler 
hepatocytes. Animal Science Journal, 87, 1490-1500. 
74 
 
LUI, C., CADY, N. C. & BATT, C. A. 2009. Nucleic acid-based detection of bacterial pathogens 
using integrated microfluidic platform systems. Sensors, 9, 3713-3744. 
MARCHESE, S., POLO, A., ARIANO, A., VELOTTO, S., COSTANTINI, S. & SEVERINO, L. 
2018. Aflatoxin B1 and M1: Biological properties and their involvement in cancer 
development. Toxins, 10, 214. 
MCILWAIN, D. R., BERGER, T. & MAK, T. W. 2013. Caspase functions in cell death and 
disease. Cold Spring Harbor perspectives in biology, 5, a008656. 
MENEELY, J. P., HAJŠLOVÁ, J., KRSKA, R. & ELLIOTT, C. T. 2018. Assessing the 
combined toxicity of the natural toxins, aflatoxin B1, fumonisin B1 and microcystin-LR 
by high content analysis. Food and chemical toxicology, 121, 527-540. 
MILKOVIC, L., CIPAK GASPAROVIC, A., CINDRIC, M., MOUTHUY, P.-A. & ZARKOVIC, 
N. 2019. Short Overview of ROS as Cell Function Regulators and Their Implications in 
Therapy Concepts. Cells, 8, 793. 
MISIHAIRABGWI, J., EZEKIEL, C., SULYOK, M., SHEPHARD, G. & KRSKA, R. 2019. 
Mycotoxin contamination of foods in Southern Africa: A 10-year review (2007–2016). 
Critical reviews in food science and nutrition, 59, 43-58. 
MOOSA, M. 2019. The state of kidney transplantation in South Africa. SAMJ: South African 
Medical Journal, 109, 235-240. 
MOOSA, M., VAN DER WALT, I., NAICKER, S. & MEYERS, A. 2015. Important causes of 
chronic kidney disease in South Africa. South African Medical Journal, 105, 320-327. 
MORGAN, M. J. & LIU, Z.-G. 2011. Crosstalk of reactive oxygen species and NF-κB signaling. 
Cell research, 21, 103. 
MUSLEH, M., AL-OUQAILI, M. & AL-KUBAISI, S. 2017. A Molecular Study of Aflatoxin and 
its Toxic Effect on Hematopoietic Stem Cells. M. Sc. Thesis, Department of Biology, 
College of Education for Pure Sciences …. 
NANDHAKUMAR, S., PARASURAMAN, S., SHANMUGAM, M., RAO, K. R., CHAND, P. 
& BHAT, B. V. 2011. Evaluation of DNA damage using single-cell gel electrophoresis 
(Comet Assay). Journal of pharmacology & pharmacotherapeutics, 2, 107. 
NAVARRO, E., SERRANO-HERAS, G., CASTAÑO, M. & SOLERA, J. 2015. Real-time PCR 
detection chemistry. Clinica chimica acta, 439, 231-250. 
PENG, X., YU, Z., LIANG, N., CHI, X., LI, X., JIANG, M., FANG, J., CUI, H., LAI, W. & 
ZHOU, Y. 2016. The mitochondrial and death receptor pathways involved in the 
thymocytes apoptosis induced by aflatoxin B1. Oncotarget, 7, 12222. 
PFEFFER, C. & SINGH, A. 2018. Apoptosis: a target for anticancer therapy. International 
journal of molecular sciences, 19, 448. 
PIZZORNO, J. 2015. The Kidney Dysfunction Epidemic, Part 1: Causes. Integrative Medicine: A 
Clinician's Journal, 14, 8. 
QURESHI, H., HAMID, S. S., ALI, S. S., ANWAR, J., SIDDIQUI, A. A. & KHAN, N. A. 2015. 
Cytotoxic effects of aflatoxin B1 on human brain microvascular endothelial cells of the 
blood-brain barrier. Medical mycology, 53, 409-416. 
RAJPUT, S., SUN, L., ZHANG, N.-Y., KHALIL, M., LING, Z., CHONG, L., WANG, S., 
RAJPUT, I., BLOCH, D. & KHAN, F. 2019. Grape Seed Proanthocyanidin Extract 
Alleviates AflatoxinB1-Induced Immunotoxicity and Oxidative Stress via Modulation of 
NF-κB and Nrf2 Signaling Pathways in Broilers. Toxins, 11, 23. 
RAMPAL, G., KHANNA, N., THIND, T. S., ARORA, S. & VIG, A. 2012. Role of 
isothiocyanates as anticancer agents and their contributing molecular and cellular 
mechanisms. Med. Chem. Drug Discovery, 3, 79-93. 
75 
 
RAUNIO, H., KUUSISTO, M., JUVONEN, R. O. & PENTIKÄINEN, O. T. 2015. Modeling of 
interactions between xenobiotics and cytochrome P450 (CYP) enzymes. Frontiers in 
pharmacology, 6, 123. 
RISS, T. L., MORAVEC, R. A., NILES, A. L., DUELLMAN, S., BENINK, H. A., 
WORZELLA, T. J. & MINOR, L. 2016. Cell viability assays. Assay Guidance Manual 
[Internet]. Eli Lilly & Company and the National Center for Advancing Translational 
Sciences. 
ROEBUCK, B. D., JOHNSON, D. N., SUTTER, C. H., EGNER, P. A., SCHOLL, P. F., 
FRIESEN, M. D., BAUMGARTNER, K. J., WARE, N. M., BODREDDIGARI, S. & 
GROOPMAN, J. D. 2009. Transgenic expression of aflatoxin aldehyde reductase 
(AKR7A1) modulates aflatoxin B1 metabolism but not hepatic carcinogenesis in the rat. 
Toxicological sciences, 109, 41-49. 
RUSHING, B. R. & SELIM, M. I. 2018. Aflatoxin B1: A review on metabolism, toxicity, 
occurrence in food, occupational exposure, and detoxification methods. Food and 
chemical toxicology. 
SAINZ, R. M., LOMBO, F. & MAYO, J. C. 2012. Radical decisions in cancer: redox control of 
cell growth and death. Cancers, 4, 442-474. 
SALBITANI, G., BOTTONE, C. & CARFAGNA, S. 2017. Determination of reduced and total 
glutathione content in extremophilic microalga Galdieria phlegrea. Bio Protoc., 7, e2372. 
SHARMA, V., SHARMA, C., PALIWAL, R., PRACHETA, S. S. & SHARMA, S. 2011. 
Ameliorative effects of Curcuma longa and curcumin on aflatoxin B1 induced serological 
and biochemical changes in kidney of male mice. Asian J Biochem Pharmaceut Res, 2, 
338-351. 
SHEN, H.-M., SHI, C.-Y., LEE, H.-P. & ONG, C.-N. 1994. Aflatoxin B1-induced lipid 
peroxidation in rat liver. Toxicology and applied pharmacology, 127, 145-150. 
SHEN, H.-M., SHI, C.-Y., SHEN, Y. & ONG, C.-N. 1996. Detection of elevated reactive oxygen 
species level in cultured rat hepatocytes treated with aflatoxin B1. Free Radical Biology 
and Medicine, 21, 139-146. 
STEPANENKO, A. & DMITRENKO, V. 2015. HEK293 in cell biology and cancer research: 
phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution. 
Gene, 569, 182-190. 
STEWART, R. K., SMITH, G. B., DONNELLY, P. J., REID, K. R., PETSIKAS, D., CONLAN, 
A. A. & MASSEY, T. E. 1999. Glutathione S-transferase-catalyzed conjugation of 
bioactivated aflatoxin B1 in human lung: differential cellular distribution and lack of 
significance of the GSTM1 genetic polymorphism. Carcinogenesis, 20, 1971-1977. 
STOCKERT, J. C., HOROBIN, R. W., COLOMBO, L. L. & BLAZQUEZ-CASTRO, A. 2018. 
Tetrazolium salts and formazan products in Cell Biology: Viability assessment, 
fluorescence imaging, and labeling perspectives. Acta histochemica, 120, 159-167. 
SZNARKOWSKA, A., KOSTECKA, A., MELLER, K. & BIELAWSKI, K. P. 2017. Inhibition 
of cancer antioxidant defense by natural compounds. Oncotarget, 8, 15996. 
SZYMAŃSKA, K., LESI, O. A., KIRK, G. D., SAM, O., TANIERE, P., SCOAZEC, J. Y., 
MENDY, M., FRIESEN, M. D., WHITTLE, H. & MONTESANO, R. 2004. Ser‐
249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from 
a high incidence area in the Gambia, West Africa. International journal of cancer, 110, 
374-379. 
TAYLOR, S. C. & POSCH, A. 2014. The design of a quantitative western blot experiment. 
BioMed research international, 2014. 
76 
 
TONG, L., CHUANG, C.-C., WU, S. & ZUO, L. 2015. Reactive oxygen species in redox cancer 
therapy. Cancer letters, 367, 18-25. 
VAN VLEET, T. R., MACÉ, K. & COULOMBE, R. A. 2002. Comparative aflatoxin B1 
activation and cytotoxicity in human bronchial cells expressing cytochromes P450 1A2 
and 3A4. Cancer research, 62, 105-112. 
VLAHOPOULOS, S., ADAMAKI, M., KHOURY, N., ZOUMPOURLIS, V. & BOLDOGH, I. 
2019. Roles of DNA repair enzyme OGG1 in innate immunity and its significance for 
lung cancer. Pharmacology & therapeutics, 194, 59-72. 
WANG, R., LI, C., QIAO, P., XUE, Y., ZHENG, X., CHEN, H., ZENG, X., LIU, W., 
BOLDOGH, I. & BA, X. 2018. OGG1-initiated base excision repair exacerbates 
oxidative stress-induced parthanatos. Cell death & disease, 9, 628. 
WANGIKAR, P., DWIVEDI, P., SINHA, N., SHARMA, A. & TELANG, A. 2005. Teratogenic 
effects in rabbits of simultaneous exposure to ochratoxin A and aflatoxin B1 with special 
reference to microscopic effects. Toxicology, 215, 37-47. 
YANG, X.-J., LU, H.-Y., LI, Z.-Y., BIAN, Q., QIU, L.-L., LI, Z., LIU, Q., LI, J., WANG, X. & 
WANG, S.-L. 2012. Cytochrome P450 2A13 mediates aflatoxin B1-induced cytotoxicity 
and apoptosis in human bronchial epithelial cells. Toxicology, 300, 138-148. 
YAO, H., HRUSKA, Z. & DI MAVUNGU, J. D. 2015. Developments in detection and 
determination of aflatoxins. World Mycotoxin Journal, 8, 181-191. 
YILMAZ, S., KAYA, E., KARACA, A. & KARATAS, O. 2018. Aflatoxin B1 induced renal and 
cardiac damage in rats: Protective effect of lycopene. Research in veterinary science, 119, 
268-275. 
YIP, K. Y., WAN, M. L. Y., WONG, A. S. T., KORACH, K. S. & EL-NEZAMI, H. 2017. 
Combined low-dose zearalenone and aflatoxin B1 on cell growth and cell-cycle 
progression in breast cancer MCF-7 cells. Toxicology letters, 281, 139-151. 
YONG, J., BISCHOF, H., BURGSTALLER, S., SIIRIN, M., MURPHY, A., MALLI, R. & 
KAUFMAN, R. J. 2019. Mitochondria supply ATP to the ER through a mechanism 
antagonized by cytosolic Ca2+. eLife, 8. 
ZANGER, U. M. & SCHWAB, M. 2013. Cytochrome P450 enzymes in drug metabolism: 
regulation of gene expression, enzyme activities, and impact of genetic variation. 
Pharmacology & therapeutics, 138, 103-141. 
ZEB, A. & ULLAH, F. 2016. A simple spectrophotometric method for the determination of 
thiobarbituric acid reactive substances in fried fast foods. Journal of analytical methods in 
chemistry, 2016. 
ZHANG, Y., CHEN, X., GUEYDAN, C. & HAN, J. 2018. Plasma membrane changes during 
programmed cell deaths. Cell research, 28, 9. 
ZHANG, Z., LU, H., HUAN, F., MEGHAN, C., YANG, X., WANG, Y., WANG, X., WANG, 
X. & WANG, S. L. 2014. Cytochrome P450 2A13 mediates the neoplastic transformation 
of human bronchial epithelial cells at a low concentration of aflatoxin B1. International 
journal of cancer, 134, 1539-1548. 
ZINEDINE, A. & EL AKHDARI, S. 2019. Food Safety and Climate Change: Case of 
Mycotoxins. Handbook of Research on Global Environmental Changes and Human 
Health. IGI Global. 
 
 
 
77 
 
 
 
APPENDIX 
 
Appendix A  
 
Table A1: MTT assay raw data used to calculate AFB1 IC50 
 
AFB1 
concentration    
(µM) 
Log 
concentration 
OD1 OD2 OD3 OD4 Average 
% cell 
viability 
0  0,23 0,219 0,245 0,265 0,2398  
1,25 0,097 0,177 0,152 0,185 0,226 0,1850 77 
2,5 0,398 0,206 0,221 0,248 0,251 0,2315 97 
5 0,699 0,206 0,261 0,209 0,288 0,2410 101 
10 1,000 0,197 0,169 0,226 0,236 0,2070 86 
25 1,398 0,108 0,107 0,133 0,097 0,1113 46 
50 1,699 0,242 0,27 0,184 0,184 0,2200 92 
75 1,875 0,247 0,162 0,13 0,12 0,1648 69 
100 2,000 0,056 0,099 0,047 0,063 0,0663 28 
 
  
Appendix B : Nitric oxide synthase (NOS)assay  
 
  
 
Figure B1 :  Standard  curve generated from NOS standards.  
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Appendix C : Protein standardisation  
 
 
 
 
Figure C1 : Protein standardisation curve   
 
Appendix D : Quantitative polymerase reaction ( qPCR) 
 
 
Figure D1 : The amplification of OGG1 gene. 
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